

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 263/58, 235/30, 413/12, 401/12, 405/12, 409/12, A61K 31/423, 31/4184, A61P 29/00, 11/06		A1	(11) International Publication Number: WO 00/49005 (43) International Publication Date: 24 August 2000 (24.08.00)
(21) International Application Number: PCT/GB00/00553 (22) International Filing Date: 16 February 2000 (16.02.00) (30) Priority Data: 9903532.1 16 February 1999 (16.02.99) GB 60/141,445 29 June 1999 (29.06.99) US (71) Applicant (for all designated States except US): AVENTIS PHARMA LIMITED [GB/GB]; Aventis House, 50 Kings Hill Avenue, Kings Hill, West Malling, Kent ME19 4AH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CLARK, David, Edward [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). EASTWOOD, Paul, Robert [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). HARRIS, Neil, Victor [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MCCARTHY, Clive [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MORLEY, Andrew, David [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Da-		genham, Essex RM10 7XS (GB). PICKETT, Stephen, Den- nis [GB/GB]; Rhone-Poulenc Rorer Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). (74) Agent: CAFFIN, Lee; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 6XS (GB). (81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report.	
(54) Title: BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS			
<div style="text-align: center;"> <p style="text-align: right;">(I)</p> </div>			
<p>(57) Abstract</p> <p>The invention is directed to physiologically active compounds of general formula (I); wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring; R¹ is optionally substituted aryl or optionally substituted heteroaryl; R² is hydrogen, halogen, lower alkyl or lower alkoxy; L¹ is an -R³-R⁴- linkage where R³ is alkylene, alkenylene or alkynylene and R⁴ is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, -C(=Z²)-NR⁵-, -NR⁵-C(=Z²)-, -Z²-, -C(=O)-, -C(=NOR⁵)-, -NR⁵-, -NR⁵-C(=Z²)-NR⁵-, -SO₂-NR⁵-, -NR⁵-SO₂-, -O-C(=O)-, -C(=O)-O-, -NR⁵-C(=O)-O- or -O-C(=O)-NR⁵-; L² is optionally substituted alkylene or alkenylene; Y is carboxy or an acid bioisostere; and Z¹ is NR⁵; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

BICYCLIC COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR LIGANDS

This invention is directed to substituted bicyclic compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of cell adhesion.

Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localise within the extra-cellular matrix. Many of the cell-cell and cell-extracellular matrix interactions are mediated by protein ligands (e.g. fibronectin, VCAM-1 and vitronectin) and their integrin receptors [e.g. $\alpha 5\beta 1$ (VLA-5), $\alpha 4\beta 1$ (VLA-4) and $\alpha V\beta 3$]. Recent studies have shown these interactions to play an important part in many physiological (e.g. embryonic development and wound healing) and pathological conditions (e.g. tumour-cell invasion and metastasis, inflammation, atherosclerosis and autoimmune disease).

A wide variety of proteins serve as ligands for integrin receptors. In general, the proteins recognised by integrins fall into one of three classes: extracellular matrix proteins, plasma proteins and cell surface proteins. Extracellular matrix proteins such as collagen fibronectin, fibrinogen, laminin, thrombospondin and vitronectin bind to a number of integrins. Many of the adhesive proteins also circulate in plasma and bind to activated blood cells. Additional components in plasma that are ligands for integrins include fibrinogen and factor X. Cell bound complement C3bi and several transmembrane proteins, such as Ig-like cell adhesion molecule (ICAM-1,2,3) and vascular cell adhesion molecule (VCAM-1), which are members of the Ig superfamily, also serve as cell-surface ligands for some integrins.

Integrins are heterodimeric cell surface receptors consisting of two subunits called α and β . There are at least fifteen different α -subunits ($\alpha 1$ - $\alpha 9$, α -L, α -M, α -X, α -IIb, α -V and α -E) and at least seven different β ($\beta 1$ - $\beta 7$) subunits. The integrin family can be subdivided into classes based on the β subunits, which can be associated with one or more α -subunits. The most widely distributed integrins belong to the $\beta 1$ class, also known as the very late antigens (VLA). The second class of integrins are leukocyte specific receptors and consist of one of three α -subunits (α -L, α -M or α -X) complexed with the $\beta 2$ protein. The cytoadhesins α -IIb $\beta 3$ and α -V $\beta 3$, constitute the third class of integrins.

The present invention principally relates to agents which modulate the interaction of the ligand VCAM-1 with its integrin receptor $\alpha 4\beta 1$ (VLA-4), which is expressed on numerous


hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils.

The integrin $\alpha 4\beta 1$ mediates both cell-cell and cell-matrix interactions. Cells expressing $\alpha 4\beta 1$ bind to the carboxy-terminal cell binding domain (CS-1) of the extracellular matrix protein fibronectin, to the cytokine-inducible endothelial cell surface protein VCAM-1, and to each other to promote homotypic aggregation. The expression of VCAM-1 by endothelial cells is upregulated by proinflammatory cytokines such as INF- γ , TNF- α , IL-1 β and IL-4.

Regulation of $\alpha 4\beta 1$ mediated cell adhesion is important in numerous physiological processes, including T-cell proliferation, B-cell localisation to germinal centres, and adhesion of activated T-cells and eosinophils to endothelial cells. Evidence for the involvement of VLA-4/VCAM-1 interaction in various disease processes such as melanoma cell division in metastasis, T-cell infiltration of synovial membranes in rheumatoid arthritis, autoimmune diabetes, colitis and leukocyte penetration of the blood-brain barrier in experimental autoimmune encephalomyelitis, atherosclerosis, peripheral vascular disease, cardiovascular disease and multiple sclerosis, has been accumulated by investigating the role of the peptide CS-1 (the variable region of fibronectin to which $\alpha 4\beta 1$ binds via the sequence Leu-Asp-Val) and antibodies specific for VLA-4 or VCAM-1 in various in vitro and in vivo experimental models of inflammation. For example, in a Streptococcal cell wall-induced experimental model of arthritis in rats, intravenous administration of CS-1 at the initiation of arthritis suppresses both acute and chronic inflammation (S.M.Wahl et al., J.Clin.Invest., 1994, 94, pages 655-662). In the oxazalone-sensitised model of inflammation (contact hypersensitivity response) in mice, intravenous administration of anti- $\alpha 4$ specific monoclonal antibodies significantly inhibited (50-60% reduction in the ear swelling response) the efferent response (P.L.Chisholm et al. J.Immunol., 1993, 23, pages 682-688). In a sheep model of allergic bronchoconstriction, HP1/2, an anti- $\alpha 4$ monoclonal antibody given intravenously or by aerosol, blocked the late response and the development of airway hyperresponsiveness (W.M. Abraham et al. J. Clin. Invest., 1994, 93 pages 776-787).

We have now found a novel group of substituted bicyclic compounds which have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ($\alpha 4\beta 1$).

Thus, in one aspect, the present invention is directed to compounds of general formula (I):-



5 wherein:-

Het represents a saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N, optionally substituted by one or more aryl group substituents;

R¹ represents optionally substituted aryl or optionally substituted heteroaryl;

10 R² represents hydrogen, halogen, lower alkyl or lower alkoxy;

R³ is an alkylene chain, an alkenylene chain or an alkynylene chain;

R⁴ is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, -C(=Z²)-NR⁵-, -NR⁵-C(=Z²)-, -Z²-, -C(=O)-, -C(=NOR⁵)-, -NR⁵-, -NR⁵-C(=Z²)-NR⁵-, -SO₂-NR⁵-, -NR⁵-SO₂-, -O-C(=O)-, -C(=O)-O-, -NR⁵-C(=O)-O- or -O-C(=O)-NR⁵-;

15 R⁵ represents hydrogen or lower alkyl;

R⁶ represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

L¹ represents a -R³-R⁴- linkage;

20 L² represents an alkylene or alkenylene linkage each optionally substituted by R⁶ or

by alkyl substituted by hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y²;

Y is carboxy or an acid bioisostere;

Y¹ and Y² are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY¹Y² may form a cyclic amine;

25 Z¹ represents NR⁵; and

Z² is O or S;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs, but excluding

compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon-carbon multiple bond of an alkenyl, alkenylene, alkynyl, alkynylene or cycloalkenyl residue.

5 In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (I) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes
10 indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:-

15

"Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in
20 Medicinal Chemistry, 1986,21,p283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993,33,p576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995,p34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995,343,p105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid
25 bioisosteres include: -C(=O)-NHOH, -C(=O)-CH₂OH, -C(=O)-CH₂SH, -C(=O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyle, tetrazolyl, arylsulphonylcarbamoyle, heteroarylsulphonylcarbamoyle, N-methoxycarbamoyle, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydroxy-1-methylpyrazolyl.

30

"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.

"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain.

Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. "Branched", as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

"Alkenylene" means an aliphatic bivalent radical derived from a straight or branched alkenyl group, in which the alkenyl group is as described herein. Exemplary alkenylene radicals include vinylene and propylene.

"Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Alkoxyalkoxy" means an alkyl-O-alkyl-O- group wherein the alkyl groups independently are as defined above. Examples of alkoxyalkoxyl include methoxymethoxy, methoxyethoxy, ethoxyethoxy and the like.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain optionally substituted by alkoxy or by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio, lower alkylsulphinyl or lower alkylsulphonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.

"Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

"Alkylenedioxy" means an -O-alkylene-O- group in which alkylene is as defined above.

Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

- 5 "Alkylsulphinyl" means an alkyl-SO- group in which the alkyl group is as previously described. Preferred alkylsulphinyl groups are those in which the alkyl group is C₁₋₄alkyl.

"Alkylsulphonyl" means an alkyl-SO₂- group in which the alkyl group is as previously described. Preferred alkylsulphonyl groups are those in which the alkyl group is C₁₋₄alkyl.

10

"Alkylsulphonylcarbamoyl" means an alkyl-SO₂-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulphonylcarbamoyl groups are those in which the alkyl group is C₁₋₄alkyl.

- 15 "Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.

"Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain.

- 20 Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butylnyl, i-butylnyl, 3-methylbut-2-ynyl, and n-pentylnyl.

- 25 "Alkynylene" means an aliphatic bivalent radical derived from a straight or branched alkynyl group, in which the alkynyl group is as described herein. Exemplary alkynylene radicals include ethynylene and propynylene.

"Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

30

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

- 35 "Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic

moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, Y^1Y^2N- , Y^1Y^2NCO- , $Y^1Y^2NSO_2-$, $Y^1Y^2N-C_{2-6}alkylene-Z^1-$, $alkylC(=O)-Y^1N-$, $alkylSO_2-Y^1N-$ or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y^1Y^2N- . When R^1 is an optionally substituted aryl group, this may particularly represent optionally substituted phenyl.

"Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred arylalkenyls contain a lower alkenyl moiety. Exemplary arylalkenyl groups include styryl and phenylallyl.

"Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C_{1-4} alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthalenemethyl.

"Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

"Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

"Arylalkynyl" means an aryl-alkynyl- group in which the aryl and alkynyl are as previously described. Exemplary arylalkynyl groups include phenylethynyl and 3-phenylbut-2-ynyl.

"Arylene" means an optionally substituted bivalent radical derived from an aryl group. Exemplary arylene groups include optionally substituted phenylene, naphthylene and

indanylene. Suitable substituents include one or more "aryl group substituents" as defined above, particularly halogen, methyl or methoxy.

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described.

5 Exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.

"Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

10

"Arylsulphinyl" means an aryl-SO- group in which the aryl group is as previously described.

"Arylsulphonyl" means an aryl-SO₂- group in which the aryl group is as previously described.

15 "Arylsulphonylcarbamoyl" means an aryl-SO₂-NH-C(=O)- group in which the aryl group is as previously described.

"Arylthio" means an aryl-S- group in which the aryl group is as previously described.

Exemplary arylthio groups include phenylthio and naphthylthio.

20

"Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen and which (i) may optionally contain an additional heteroatom selected from O, S or NY³ (where Y³ is hydrogen, alkyl, arylalkyl, and aryl) and (ii) may be fused to additional aryl or heteroaryl ring to form a bicyclic ring system. Exemplary
25 cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline and pyrindoline.

"Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.

30

"Cycloalkenylalkyl" means a cycloalkenyl-alkyl- group in which the cycloalkenyl and alkyl moieties are as previously described. Exemplary cycloalkenylalkyl groups include cyclopentenylmethyl, cyclohexenylmethyl or cycloheptenylmethyl.

"Cycloalkenylene" means a bivalent radical derived from an unsaturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring. Exemplary cycloalkenylene radicals include cyclopentenylene and cyclohexenylene.

5

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C₃₋₈cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

10 "Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

15 "Cycloalkylene" means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 3 to about 10 carbon atoms by removing a hydrogen atom from each of two different carbon atoms of the ring. Exemplary cycloalkenylene radicals include cyclopentenylene and cyclohexenylene.

20 "Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.

20

"Heteroaryl" means a heteroaryl-C(=O)- group in which the heteroaryl group is as described herein. Exemplary groups include pyridylcarbonyl.

25 "Heteroaryl-amino" means a heteroaryl-NH- group in which the heteroaryl moiety are as previously described.

30 "Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, indolyl, indolizyl, isoxazolyl, isoquinolinyl, isothiazolyl, oxadiazolyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, quinazolinyl, quinolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a

35

cyclic structure (examples of such groups include pyridanyl groups). Optional substituents include one or more "aryl group substituents" as defined above.

"Heteroarylalkenyl" means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as previously described. Preferred heteroarylalkenyl groups contain a lower alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylethenyl and pyridylallyl.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C₁₋₄alkyl moiety.

Exemplary heteroarylalkyl groups include pyridylmethyl.

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroalkyloxy groups include optionally substituted pyridylmethoxy.

"Heteroarylalkynyl" means a heteroaryl-alkynyl- group in which the heteroaryl and alkynyl moieties are as previously described. Exemplary heteroarylalkenyl groups include pyridylethynyl and 3-pyridylbut-2-ynyl.

"Heteroaryldiyl" means a bivalent radical derived from an aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur, and optionally substituted by one or more "aryl group substituents" as defined above.

"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

"Heteroarylsulphonylcarbamoyl" means a heteroaryl-SO₂-NH-C(=O)- group in which the heteroaryl group is as previously described.

"Heterocycle" denotes an optionally substituted saturated, partially saturated or fully unsaturated monocyclic organic moiety of 5 or 6 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur.

Exemplary 5 or 6 membered heterocycles include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, oxazinyl, piperidinyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl,

pyrimidinyl, pyrrolyl, pyrrolidinyl, pyrrolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups. Optional substituents include one or more "aryl group substituents" as defined above.

"Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY³; (ii) an optionally substituted partially saturated multicyclic heterocarbo-cyclic moiety in which an aryl (or heteroaryl ring) and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indoliny and pyrindoliny groups).

"Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

"Heterocycloalkylene" means a bivalent radical derived from a saturated monocyclic hydrocarbon of about 5 to about 7 atoms, which contains one or more heteroatoms selected from O, S or NY⁴ (where Y⁴ is hydrogen, alkyl, arylalkyl, and aryl) and is optionally substituted by oxo, by removing a hydrogen atom from each of two different carbon atoms of the ring, or when NY⁴ is NH by removing a hydrogen atom from one carbon atom of the ring and a hydrogen atom from the NH, or when the ring contains two NY⁴ heteroatoms and NY⁴ is NH by removing a hydrogen atom from both nitrogen atoms.

"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (I), including N-oxides thereof. For example an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to the parent molecule. Alternatively an ester of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

Suitable esters of compounds of formula (I) containing a hydroxy group, are for example acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- β -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinate.

Suitable esters of compounds of formula (I) containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.

Suitable esters of compounds of formula (I) containing both a carboxy group and a hydroxy group within the moiety $-L^2-Y$, include lactones, formed by loss of water between said carboxy and hydroxy groups. Examples of lactones include caprolactones and butyrolactones.

- 5 An especially useful class of esters of compounds of formula (I) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem., 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated
- 10 nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or 4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or 4-(4-alkylpiperazin-1-yl)benzoates.

- Where the compound of the invention contains a carboxy group, or a sufficiently acidic
- 15 bioisostere, base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form. The bases which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory
- 20 effects inherent in the free base are not vitiated by side effects ascribable to the cations. Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-
- 25 glucamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

- 30 Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

- Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid
- 35 addition salts include preferably those which produce, when combined with the free base,




pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoilytartrates, methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinate.


As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.


With reference to formula (I) above, the following are particular and preferred groupings:

R^1 may particularly represent optionally substituted aryl, especially optionally substituted phenyl.


Z^1 may particularly represent NH.



Het may particularly represent , wherein ring  is a 5 or 6 membered heterocycle and ring  is a 5 or 6 membered fully unsaturated heterocycle or a benzene ring, each ring optionally substituted by one or more "aryl group substituents" as defined above, and the two rings are joined together by a carbon-carbon linkage or a carbon-nitrogen linkage.


Ring  may particularly represent a 5 membered fully unsaturated heterocycle.


Ring  may particularly represent a benzene ring, optionally substituted by one or more "aryl group substituents" as defined above.

5

 may particularly represent a 9 membered bicyclic system in which rings

 and  are as defined just above and the two rings are joined together by carbon

atom linkages.  is preferably benzoxazolyl or benzimidazolyl, in which ring

 is optionally substituted by one or more "aryl group substituents" as defined above

10 [examples of particular aryl group substituents include C₁₋₄ alkyl (e.g. methyl or ethyl), C₁₋₄ alkoxy (e.g. methoxy), amino, halogen, hydroxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulphanyl, C₁₋₄ alkylsulphonyl, nitro or trifluoromethyl].

15 L¹ may particularly represent a -R³-R⁴- linkage where R³ represents a straight or branched C₁₋₆alkylene chain, especially a straight or branched C₁₋₄alkylene chain, and R⁴ represents -C(=Z²)-NR⁵-, preferably -C(=O)-NR⁵-, especially where R⁵ is hydrogen or C₁₋₄ alkyl, more especially hydrogen.

R² may particularly represent hydrogen.

20

L² may particularly represent an optionally substituted alkylene linkage, especially optionally substituted ethylene. Preferred optional substituents include C₁₋₄ alkyl (e.g. methyl), aryl (e.g. optionally substituted phenyl), or alkyl substituted by hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y².

L^2 is preferably a group $\begin{array}{c} R^7 \\ | \\ -C-CH_2- \\ | \\ R^8 \end{array}$, where R^7 is hydrogen or C_{1-4} alkyl (e.g. methyl) and


R^8 represents hydrogen or C_{1-4} alkyl (e.g. methyl); or where R^7 is hydrogen and R^8 represents aryl (e.g. optionally substituted phenyl) or alkyl substituted by hydroxy, $-OR^4$, $-O-C(=O)-R^6$ or $-NY^1Y^2$. L^2 is more preferably a group $\begin{array}{c} -CH-CH_2- \\ | \\ R^8 \end{array}$ where R^8 represents C_{1-4} alkyl (e.g.

5 methyl), aryl (e.g. optionally substituted phenyl), or alkyl substituted by hydroxy, $-OR^6$, $-O-C(=O)-R^6$ or $-NY^1Y^2$.

Y may particularly represent carboxy.

10 It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

A particular group of compounds of the invention are compounds of formula (Ia):-



(Ia)

15 in which R^1 , R^2 , R^3 , R^5 , L^2 , Y and Z^1 are as hereinbefore defined, R^{13} is hydrogen or an aryl group substituent and X is O or NR^9 (in which R^9 is hydrogen or C_{1-4} alkyl), and their
20 prodrugs and pharmaceutically acceptable salts, and solvates (e.g. hydrates) of compounds of formula (Ia) and their prodrugs.

Compounds of formula (Ia) in which R^1 represents optionally substituted aryl, especially optionally substituted phenyl, are preferred. Preferred optional substituents include C_{1-4} alkyl

(e.g. methyl), C₁₋₄ alkyl (e.g. methoxy), halo (e.g. fluoro) and Y¹Y²N- (e.g. dimethylamino). R¹ especially represents ortho-tolyl.

Compounds of formula (Ia) in which Z¹ represents NH are preferred.

5

Compounds of formula (Ia) in which R¹³ represents hydrogen, C₁₋₄ alkyl (e.g. methyl or ethyl) or C₁₋₄ alkoxy (e.g. methoxy) are preferred.

Compounds of formula (Ia) in which R³ represents a straight or branched C₁₋₆alkylene chain, especially a straight or branched C₁₋₄alkylene chain, more especially methylene, are preferred.

10

Compounds of formula (Ia) in which R⁵ represents hydrogen are preferred.

Compounds of formula (Ia) in which R² represents hydrogen are preferred.

15

Compounds of formula (Ia) in which L² represents an optionally substituted alkylene linkage, especially ethylene or substituted ethylene, are preferred. Preferred optional substituents include C₁₋₄ alkyl (e.g. methyl), aryl (e.g. optionally substituted phenyl) or alkyl substituted by hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y². Compounds of formula (Ia) in which L² is a


20 $\begin{array}{c} \text{R}^7 \\ | \\ \text{---C---CH}_2\text{---} \\ | \\ \text{R}^8 \end{array}$ linkage, where R⁷ is hydrogen or C₁₋₄ alkyl (e.g. methyl) and R⁸ represents

hydrogen or C₁₋₄ alkyl (e.g. methyl), or where R⁷ is hydrogen and R⁸ represents aryl (e.g. optionally substituted phenyl) or alkyl substituted by hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y² are particularly preferred. Compounds of formula (Ia) in which L² is a $\begin{array}{c} \text{---CH---CH}_2\text{---} \\ | \\ \text{R}^8 \end{array}$ linkage,

where R⁸ represents C₁₋₄ alkyl (e.g. methyl), aryl (e.g. optionally substituted phenyl), or alkyl substituted hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y², are especially preferred.

25


Compounds of formula (Ia) in which Y represents carboxy are preferred.




when X is O or NH, or at the ring 5 or 6 position when X is NR⁹ and R⁹ is C₁₋₄ alkyl.

- 5 The group $\text{---L}^2\text{---Y}$ may preferably be attached at the 4' position of the phenyl ring.

A preferred group of compounds of the invention are compounds of formula (Ia) in which:- R¹ is optionally substituted phenyl (especially C₁₋₄ alkyl substituted phenyl, more especially ortho-tolyl); Z¹ is NH; X is O; R¹³ represents hydrogen, C₁₋₄ alkyl (e.g. methyl or ethyl) or C₁₋₄alkoxy (e.g. methoxy); R³ is a straight or branched C₁₋₄alkylene chain, (especially methylene); R⁵ is





group, where R⁸ represents hydrogen, C₁₋₄ alkyl (especially methyl), aryl (e.g. optionally substituted phenyl) or alkyl substituted by hydroxy, -OR⁶, -O-C(=O)-R⁶ or -NY¹Y²; Y is




- 15 group $\text{---L}^2\text{---Y}$ is attached at the 4' position of the phenyl ring; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

- Another preferred group of compounds of the invention are compounds of formula (Ia) in which:- R¹ is optionally substituted phenyl (especially C₁₋₄ alkyl substituted phenyl, more especially ortho-tolyl); Z¹ is NH; X is NR⁹ (especially NH); R¹³ represents hydrogen, C₁₋₄ alkyl (e.g. methyl or ethyl) or C₁₋₄ alkoxy (e.g. methoxy); R³ is a straight or branched C₁₋₄alkylene

chain, (especially methylene); R^5 is hydrogen; R^2 is hydrogen; L^2 is a  group or

preferably a  group, where R^8 represents hydrogen, C_{1-4} alkyl (especially

methyl), aryl (e.g. optionally substituted phenyl) or alkyl substituted by hydroxy, $-OR^6$,







$-O-C(=O)-R^6$ or $-NY^1Y^2$; Y is carboxy; the group  is attached

















- 5 at the ring 5 or 6 position; and the group $-L^2-Y$ is attached at the 4' position of the phenyl ring; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

- 10 Particular compounds of the invention are selected from the compounds formed by joining the acyl carbon atom (C^*) of one of the fragments (A1 to A36) shown in Table 1 to the nitrogen atom (N^*) of one of the fragments (B1 to B4) shown in Table 2, and joining the carbon atom (C^*) of the phenyl ring in one of the fragments (B1 to B4) shown in Table 2 to the carbon atom (C^*) of one of the acidic fragments (C1 to C27) depicted in Table 3.

15

TABLE 1

A1		A2	
A3		A4	
A5		A6	

A7		A8	
A9		A10	
A11		A12	
A13		A14	
A15		A16	
A17		A18	
A19		A20	
A21		A22	















A23		A24	
A25		A26	
A27		A28	
A29		A30	
A31		A32	
A33		A34	
A35		A36	

TABLE 2






















B1		B2	
B3		B4	

TABLE 3

C1	$*CH_2-CH_2-CO_2H$	C2	$*CH_2-CH_2-CH_2-CO_2H$
C3	$*CH-CH_2-CO_2H$ CH_3	C4	$*CH-CH_2-CO_2H$ CH_2CH_3
C5	$*CH-CH_2-CO_2H$ $CH(CH_3)_2$	C6	$*CH-CH_2-CO_2H$ $CH_2CH(CH_3)_2$
C7	$*CH-CH_2-CO_2H$ $C(CH_3)_3$	C8	$*CH-CH_2-CO_2H$ $CH_2C(CH_3)_3$
C9	$*CH-CH_2-CO_2H$ 	C10	$*CH-CH_2-CO_2H$ 
C11	$*CH-CH_2-CO_2H$ 	C12	$*CH-CH_2-CO_2H$ 
C13	$*CH-CH_2-CO_2H$ 	C14	$*CH-CH_2-CO_2H$ 

C15	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C16	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 
C17	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C18	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 
C19	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C20	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 
C21	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C22	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 
C23	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C24	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 
C25	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ 	C26	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ $\text{CH}_2\text{CO}_2\text{H}$
C27	$\text{*CH}-\text{CH}_2-\text{CO}_2\text{H}$ $\text{CH}_2\text{CH}_2\text{CH}_2\text{OH}$		

Particularly preferred examples of fragments "A", "B", and "C" are illustrated below:

A1-B1-C1; A1-B1-C2; A1-B1-C3; A1-B1-C4; A1-B1-C5; A1-B1-C6;
 A1-B1-C7; A1-B1-C8; A1-B1-C9; A1-B1-C10; A1-B1-C11; A1-B1-C12;
 A1-B1-C13; A1-B1-C14; A1-B1-C15; A1-B1-C16; A1-B1-C17; A1-B1-C18;
 A1-B1-C19; A1-B1-C20; A1-B1-C21; A1-B1-C22; A1-B1-C23; A1-B1-C24;
 A1-B1-C25; A1-B1-C26; A1-B1-C27; A2-B1-C1; A2-B1-C2; A2-B1-C3;
 A2-B1-C4; A2-B1-C5; A2-B1-C6; A2-B1-C7 A2-B1-C8; A2-B1-C9;

A2-B1-C10;	A2-B1-C11;	A2-B1-C12;	A2-B1-C13;	A2-B1-C14;	A2-B1-C15;
A2-B1-C16;	A2-B1-C17;	A2-B1-C18;	A2-B1-C19;	A2-B1-C20;	A2-B1-C21;
A2-B1-C22;	A2-B1-C23;	A2-B1-C24;	A2-B1-C25;	A2-B1-C26;	A2-B1-C27;
A3-B1-C1;	A3-B1-C2;	A3-B1-C3;	A3-B1-C4;	A3-B1-C5;	A3-B1-C6;
A3-B1-C7;	A3-B1-C8;	A3-B1-C9;	A3-B1-C10;	A3-B1-C11;	A3-B1-C12;
A3-B1-C13;	A3-B1-C14;	A3-B1-C15;	A3-B1-C16;	A3-B1-C17;	A3-B1-C18;
A3-B1-C19;	A3-B1-C20;	A3-B1-C21;	A3-B1-C22;	A3-B1-C23;	A3-B1-C24;
A3-B1-C25;	A3-B1-C26;	A3-B1-C27;	A4-B1-C1;	A4-B1-C2;	A4-B1-C3;
A4-B1-C4;	A4-B1-C5;	A4-B1-C6;	A4-B1-C7;	A4-B1-C8;	A4-B1-C9;
A4-B1-C10;	A4-B1-C11;	A4-B1-C12;	A4-B1-C13;	A4-B1-C14;	A4-B1-C15;
A4-B1-C16;	A4-B1-C17;	A4-B1-C18;	A4-B1-C19;	A4-B1-C20;	A4-B1-C21;
A4-B1-C22;	A4-B1-C23;	A4-B1-C24;	A4-B1-C25;	A4-B1-C26;	A4-B1-C27;
A5-B1-C1;	A5-B1-C2;	A5-B1-C3;	A5-B1-C4;	A5-B1-C5;	A5-B1-C6;
A5-B1-C7;	A5-B1-C8;	A5-B1-C9;	A5-B1-C10;	A5-B1-C11;	A5-B1-C12;
A5-B1-C13;	A5-B1-C14;	A5-B1-C15;	A5-B1-C16;	A5-B1-C17;	A5-B1-C18;
A5-B1-C19;	A5-B1-C20;	A5-B1-C21;	A5-B1-C22;	A5-B1-C23;	A5-B1-C24;
A5-B1-C25;	A5-B1-C26;	A5-B1-C27;	A6-B1-C1;	A6-B1-C2;	A6-B1-C3;
A6-B1-C4;	A6-B1-C5;	A6-B1-C6;	A6-B1-C7;	A6-B1-C8;	A6-B1-C9;
A6-B1-C10;	A6-B1-C11;	A6-B1-C12;	A6-B1-C13;	A6-B1-C14;	A6-B1-C15;
A6-B1-C16;	A6-B1-C17;	A6-B1-C18;	A6-B1-C19;	A6-B1-C20;	A6-B1-C21;
A6-B1-C22;	A6-B1-C23;	A6-B1-C24;	A6-B1-C25;	A5-B1-C26;	A5-B1-C27;
A7-B1-C1;	A7-B1-C2;	A7-B1-C3;	A7-B1-C4;	A7-B1-C5;	A7-B1-C6;
A7-B1-C7;	A7-B1-C8;	A7-B1-C9;	A7-B1-C10;	A7-B1-C11;	A7-B1-C12;
A7-B1-C13;	A7-B1-C14;	A7-B1-C15;	A7-B1-C16;	A7-B1-C17;	A7-B1-C18;
A7-B1-C19;	A7-B1-C20;	A7-B1-C21;	A7-B1-C22;	A7-B1-C23;	A7-B1-C24;
A7-B1-C25;	A7-B1-C26;	A7-B1-C27;	A8-B1-C1;	A8-B1-C2;	A8-B1-C3;
A8-B1-C4;	A8-B1-C5;	A8-B1-C6;	A8-B1-C7;	A8-B1-C8;	A8-B1-C9;
A8-B1-C10;	A8-B1-C11;	A8-B1-C12;	A8-B1-C13;	A8-B1-C14;	A8-B1-C15;
A8-B1-C16;	A8-B1-C17;	A8-B1-C18;	A8-B1-C19;	A8-B1-C20;	A8-B1-C21;
A8-B1-C22;	A8-B1-C23;	A8-B1-C24;	A8-B1-C25;	A8-B1-C26;	A8-B1-C27;
A9-B1-C1;	A9-B1-C2;	A9-B1-C3;	A9-B1-C4;	A9-B1-C5;	A9-B1-C6;
A9-B1-C7;	A9-B1-C8;	A9-B1-C9;	A9-B1-C10;	A9-B1-C11;	A9-B1-C12;
A9-B1-C13;	A9-B1-C14;	A9-B1-C15;	A9-B1-C16;	A9-B1-C17;	A9-B1-C18;
A9-B1-C19;	A9-B1-C20;	A9-B1-C21;	A9-B1-C22;	A9-B1-C23;	A9-B1-C24;
A9-B1-C25;	A9-B1-C26;	A9-B1-C27;	A10-B1-C1;	A10-B1-C2;	A10-B1-C3;

A10-B1-C4; A10-B1-C5; A10-B1-C6; A10-B1-C7; A10-B1-C8; A10-B1-C9;
A10-B1-C10; A10-B1-C11; A10-B1-C12; A10-B1-C13; A10-B1-C14; A10-B1-C15;
A10-B1-C16; A10-B1-C17; A10-B1-C18; A10-B1-C19; A10-B1-C20; A10-B1-C21;
A10-B1-C22; A10-B1-C23; A10-B1-C24; A10-B1-C25; A10-B1-C26; A10-B1-C27;
A11-B1-C1; A11-B1-C2; A11-B1-C3; A11-B1-C4; A11-B1-C5; A11-B1-C6;
A11-B1-C7; A11-B1-C8; A11-B1-C9; A11-B1-C10; A11-B1-C11; A11-B1-C12;
A11-B1-C13; A11-B1-C14; A11-B1-C15; A11-B1-C16; A11-B1-C17; A11-B1-C18;
A11-B1-C19; A11-B1-C20; A11-B1-C21; A11-B1-C22; A11-B1-C23; A11-B1-C24;
A11-B1-C25; A11-B1-C26; A11-B1-C27; A12-B1-C1; A12-B1-C2; A12-B1-C3;
A12-B1-C4; A12-B1-C5; A12-B1-C6; A12-B1-C7; A12-B1-C8; A12-B1-C9;
A12-B1-C10; A12-B1-C11; A12-B1-C12; A12-B1-C13; A12-B1-C14; A12-B1-C15;
A12-B1-C16; A12-B1-C17; A12-B1-C18; A12-B1-C19; A12-B1-C20; A12-B1-C21;
A12-B1-C22; A12-B1-C23; A12-B1-C24; A12-B1-C25; A12-B1-C26; A12-B1-C27;
A13-B1-C1; A13-B1-C2; A13-B1-C3; A13-B1-C4; A13-B1-C5; A13-B1-C6;
A13-B1-C7; A13-B1-C8; A13-B1-C9; A13-B1-C10; A13-B1-C11; A13-B1-C12;
A13-B1-C13; A13-B1-C14; A13-B1-C15; A13-B1-C16; A13-B1-C17; A13-B1-C18;
A13-B1-C19; A13-B1-C20; A13-B1-C21; A13-B1-C22; A13-B1-C23; A13-B1-C24;
A13-B1-C25; A13-B1-C26; A13-B1-C27; A14-B1-C1; A14-B1-C2; A14-B1-C3;
A14-B1-C4; A14-B1-C5; A14-B1-C6; A14-B1-C7; A14-B1-C8; A14-B1-C9;
A14-B1-C10; A14-B1-C11; A14-B1-C12; A14-B1-C13; A14-B1-C14; A14-B1-C15;
A14-B1-C16; A14-B1-C17; A14-B1-C18; A14-B1-C19; A14-B1-C20; A14-B1-C21;
A14-B1-C22; A14-B1-C23; A14-B1-C24; A14-B1-C25; A14-B1-C26; A14-B1-C27;
A15-B1-C1; A15-B1-C2; A15-B1-C3; A15-B1-C4; A15-B1-C5; A15-B1-C6;
A15-B1-C7; A15-B1-C8; A15-B1-C9; A15-B1-C10; A15-B1-C11; A15-B1-C12;
A15-B1-C13; A15-B1-C14; A15-B1-C15; A15-B1-C16; A15-B1-C17; A15-B1-C18;
A15-B1-C19; A15-B1-C20; A15-B1-C21; A15-B1-C22; A15-B1-C23; A15-B1-C24;
A15-B1-C25; A15-B1-C26; A15-B1-C27; A16-B1-C1; A16-B1-C2; A16-B1-C3;
A16-B1-C4; A16-B1-C5; A16-B1-C6; A16-B1-C7; A16-B1-C8; A16-B1-C9;
A16-B1-C10; A16-B1-C11; A16-B1-C12; A16-B1-C13; A16-B1-C14; A16-B1-C15;
A16-B1-C16; A16-B1-C17; A16-B1-C18; A16-B1-C19; A16-B1-C20; A16-B1-C21;
A16-B1-C22; A16-B1-C23; A16-B1-C24; A16-B1-C25; A16-B1-C26; A16-B1-C27;
A17-B1-C1; A17-B1-C2; A17-B1-C3; A17-B1-C4; A17-B1-C5; A17-B1-C6;
A17-B1-C7; A17-B1-C8; A17-B1-C9; A17-B1-C10; A17-B1-C11; A17-B1-C12;
A17-B1-C13; A17-B1-C14; A17-B1-C15; A17-B1-C16; A17-B1-C17; A17-B1-C18;
A17-B1-C19; A17-B1-C20; A17-B1-C21; A17-B1-C22; A17-B1-C23; A17-B1-C24;

A17-B1-C25; A17-B1-C26; A17-B1-C27; A18-B1-C1; A18-B1-C2; A18-B1-C3;
A18-B1-C4; A18-B1-C5; A18-B1-C6; A18-B1-C7; A18-B1-C8; A18-B1-C9;
A18-B1-C10; A18-B1-C11; A18-B1-C12; A18-B1-C13; A18-B1-C14; A18-B1-C15;
A18-B1-C16; A18-B1-C17; A18-B1-C18; A18-B1-C19; A18-B1-C20; A18-B1-C21;
A18-B1-C22; A18-B1-C23; A18-B1-C24; A18-B1-C25; A18-B1-C26; A18-B1-C27;
A19-B1-C1; A19-B1-C2; A19-B1-C3; A19-B1-C4; A19-B1-C5; A19-B1-C6;
A19-B1-C7; A19-B1-C8; A19-B1-C9; A19-B1-C10; A19-B1-C11; A19-B1-C12;
A19-B1-C13; A19-B1-C14; A19-B1-C15; A19-B1-C16; A19-B1-C17; A19-B1-C18;
A19-B1-C19; A19-B1-C20; A19-B1-C21; A19-B1-C22; A19-B1-C23; A19-B1-C24;
A19-B1-C25; A19-B1-C26; A19-B1-C27; A20-B1-C1; A20-B1-C2; A20-B1-C3;
A20-B1-C4; A20-B1-C5; A20-B1-C6; A20-B1-C7; A20-B1-C8; A20-B1-C9;
A20-B1-C10; A20-B1-C11; A20-B1-C12; A20-B1-C13; A20-B1-C14; A20-B1-C15;
A20-B1-C16; A20-B1-C17; A20-B1-C18; A20-B1-C19; A20-B1-C20; A20-B1-C21;
A20-B1-C22; A20-B1-C23; A20-B1-C24; A20-B1-C25; A20-B1-C26; A20-B1-C27;
A21-B1-C1; A21-B1-C2; A21-B1-C3; A21-B1-C4; A21-B1-C5; A21-B1-C6;
A21-B1-C7; A21-B1-C8; A21-B1-C9; A21-B1-C10; A21-B1-C11; A21-B1-C12;
A21-B1-C13; A21-B1-C14; A21-B1-C15; A21-B1-C16; A21-B1-C17; A21-B1-C18;
A21-B1-C19; A21-B1-C20; A21-B1-C21; A21-B1-C22; A21-B1-C23; A21-B1-C24;
A21-B1-C25; A21-B1-C26; A21-B1-C27; A22-B1-C1; A22-B1-C2; A22-B1-C3;
A22-B1-C4; A22-B1-C5; A22-B1-C6; A22-B1-C7; A22-B1-C8; A22-B1-C9;
A22-B1-C10; A22-B1-C11; A22-B1-C12; A22-B1-C13; A22-B1-C14; A22-B1-C15;
A22-B1-C16; A22-B1-C17; A22-B1-C18; A22-B1-C19; A22-B1-C20; A22-B1-C21;
A22-B1-C22; A22-B1-C23; A22-B1-C24; A22-B1-C25; A22-B1-C26; A22-B1-C27;
A23-B1-C1; A23-B1-C2; A23-B1-C3; A23-B1-C4; A23-B1-C5; A23-B1-C6;
A23-B1-C7; A23-B1-C8; A23-B1-C9; A23-B1-C10; A23-B1-C11; A23-B1-C12;
A23-B1-C13; A23-B1-C14; A23-B1-C15; A23-B1-C16; A23-B1-C17; A23-B1-C18;
A23-B1-C19; A23-B1-C20; A23-B1-C21; A23-B1-C22; A23-B1-C23; A23-B1-C24;
A23-B1-C25; A23-B1-C26; A23-B1-C27; A24-B1-C1; A24-B1-C2; A24-B1-C3;
A24-B1-C4; A24-B1-C5; A24-B1-C6; A24-B1-C7; A24-B1-C8; A24-B1-C9;
A24-B1-C10; A24-B1-C11; A24-B1-C12; A24-B1-C13; A24-B1-C14; A24-B1-C15;
A24-B1-C16; A24-B1-C17; A24-B1-C18; A24-B1-C19; A24-B1-C20; A24-B1-C21;
A24-B1-C22; A24-B1-C23; A24-B1-C24; A24-B1-C25; A24-B1-C26; A24-B1-C27;
A25-B1-C1; A25-B1-C2; A25-B1-C3; A25-B1-C4; A25-B1-C5; A25-B1-C6;
A25-B1-C7; A25-B1-C8; A25-B1-C9; A25-B1-C10; A25-B1-C11; A25-B1-C12;
A25-B1-C13; A25-B1-C14; A25-B1-C15; A25-B1-C16; A25-B1-C17; A25-B1-C18;

A25-B1-C19; A25-B1-C20; A25-B1-C21; A25-B1-C22; A25-B1-C23; A25-B1-C24;
A25-B1-C25; A25-B1-C26; A25-B1-C27; A26-B1-C1; A26-B1-C2; A26-B1-C3;
A26-B1-C4; A26-B1-C5; A26-B1-C6; A26-B1-C7; A26-B1-C8; A26-B1-C9;
A26-B1-C10; A26-B1-C11; A26-B1-C12; A26-B1-C13; A26-B1-C14; A26-B1-C15;
A26-B1-C16; A26-B1-C17; A26-B1-C18; A26-B1-C19; A26-B1-C20; A26-B1-C21;
A26-B1-C22; A26-B1-C23; A26-B1-C24; A26-B1-C25; A26-B1-C26; A26-B1-C27;
A27-B1-C1; A27-B1-C2; A27-B1-C3; A27-B1-C4; A27-B1-C5; A27-B1-C6;
A27-B1-C7; A27-B1-C8; A27-B1-C9; A27-B1-C10; A27-B1-C11; A27-B1-C12;
A27-B1-C13; A27-B1-C14; A27-B1-C15; A27-B1-C16; A27-B1-C17; A27-B1-C18;
A27-B1-C19; A27-B1-C20; A27-B1-C21; A27-B1-C22; A27-B1-C23; A27-B1-C24;
A27-B1-C25; A27-B1-C26; A27-B1-C27; A28-B1-C1; A28-B1-C2; A28-B1-C3;
A28-B1-C4; A28-B1-C5; A28-B1-C6; A28-B1-C7; A28-B1-C8; A28-B1-C9;
A28-B1-C10; A28-B1-C11; A28-B1-C12; A28-B1-C13; A28-B1-C14; A28-B1-C15;
A28-B1-C16; A28-B1-C17; A28-B1-C18; A28-B1-C19; A28-B1-C20; A28-B1-C21;
A28-B1-C22; A28-B1-C23; A28-B1-C24; A28-B1-C25; A28-B1-C26; A28-B1-C27;
A29-B1-C1; A29-B1-C2; A29-B1-C3; A29-B1-C4; A29-B1-C5; A29-B1-C6;
A29-B1-C7; A29-B1-C8; A29-B1-C9; A29-B1-C10; A29-B1-C11; A29-B1-C12;
A29-B1-C13; A29-B1-C14; A29-B1-C15; A29-B1-C16; A29-B1-C17; A29-B1-C18;
A29-B1-C19; A29-B1-C20; A29-B1-C21; A29-B1-C22; A29-B1-C23; A29-B1-C24;
A29-B1-C25; A29-B1-C26; A29-B1-C27; A30-B1-C1; A30-B1-C2; A30-B1-C3;
A30-B1-C4; A30-B1-C5; A30-B1-C6; A30-B1-C7; A30-B1-C8; A30-B1-C9;
A30-B1-C10; A30-B1-C11; A30-B1-C12; A30-B1-C13; A30-B1-C14; A30-B1-C15;
A30-B1-C16; A30-B1-C17; A30-B1-C18; A30-B1-C19; A30-B1-C20; A30-B1-C21;
A30-B1-C22; A30-B1-C23; A30-B1-C24; A30-B1-C25; A30-B1-C26; A30-B1-C27;
A31-B1-C1; A31-B1-C2; A31-B1-C3; A31-B1-C4; A31-B1-C5; A31-B1-C6;
A31-B1-C7; A31-B1-C8; A31-B1-C9; A31-B1-C10; A31-B1-C11; A31-B1-C12;
A31-B1-C13; A31-B1-C14; A31-B1-C15; A31-B1-C16; A31-B1-C17; A31-B1-C18;
A31-B1-C19; A31-B1-C20; A31-B1-C21; A31-B1-C22; A31-B1-C23; A31-B1-C24;
A31-B1-C25; A31-B1-C26; A31-B1-C27; A32-B1-C1; A32-B1-C2; A32-B1-C3;
A32-B1-C4; A32-B1-C5; A32-B1-C6; A32-B1-C7; A32-B1-C8; A32-B1-C9;
A32-B1-C10; A32-B1-C11; A32-B1-C12; A32-B1-C13; A32-B1-C14; A32-B1-C15;
A32-B1-C16; A32-B1-C17; A32-B1-C18; A32-B1-C19; A32-B1-C20; A32-B1-C21;
A32-B1-C22; A32-B1-C23; A32-B1-C24; A32-B1-C25; A32-B1-C26; A32-B1-C27;
A33-B1-C1; A33-B1-C2; A33-B1-C3; A33-B1-C4; A33-B1-C5; A33-B1-C6;
A33-B1-C7; A33-B1-C8; A33-B1-C9; A33-B1-C10; A33-B1-C11; A33-B1-C12;

A33-B1-C13; A33-B1-C14; A33-B1-C15; A33-B1-C16; A33-B1-C17; A33-B1-C18;
A33-B1-C19; A33-B1-C20; A33-B1-C21; A33-B1-C22; A33-B1-C23; A33-B1-C24;
A33-B1-C25; A33-B1-C26; A33-B1-C27; A34-B1-C1; A34-B1-C2; A34-B1-C3;
A34-B1-C4; A34-B1-C5; A34-B1-C6; A34-B1-C7; A34-B1-C8; A34-B1-C9
A34-B1-C10; A34-B1-C11; A34-B1-C12; A34-B1-C13; A34-B1-C14; A34-B1-C15;
A34-B1-C16; A34-B1-C17; A34-B1-C18; A34-B1-C19; A34-B1-C20; A34-B1-C21;
A34-B1-C22; A34-B1-C23; A34-B1-C24; A34-B1-C25; A34-B1-C26; A34-B1-C27;
A35-B1-C1; A35-B1-C2; A35-B1-C3; A35-B1-C4; A35-B1-C5; A35-B1-C6;
A35-B1-C7; A35-B1-C8; A35-B1-C9; A35-B1-C10; A35-B1-C11; A35-B1-C12;
A35-B1-C13; A35-B1-C14; A35-B1-C15; A35-B1-C16; A35-B1-C17; A35-B1-C18;
A35-B1-C19; A35-B1-C20; A35-B1-C21; A35-B1-C22; A35-B1-C23; A35-B1-C24;
A35-B1-C25; A35-B1-C26; A35-B1-C27; A36-B1-C1; A36-B1-C2; A36-B1-C3;
A36-B1-C4; A36-B1-C5; A36-B1-C6; A36-B1-C7; A36-B1-C8; A36-B1-C9;
A36-B1-C10; A36-B1-C11; A36-B1-C12; A36-B1-C13; A36-B1-C14; A36-B1-C15;
A36-B1-C16; A36-B1-C17; A36-B1-C18; A36-B1-C19; A36-B1-C20; A36-B1-C21;
A36-B1-C22; A36-B1-C23; A36-B1-C24; A36-B1-C25; A36-B1-C26; A36-B1-C27;
A1-B2-C1; A1-B2-C2; A1-B2-C3; A1-B2-C4; A1-B2-C5; A1-B2-C6;
A1-B2-C7; A1-B2-C8; A1-B2-C9; A1-B2-C10; A1-B2-C11; A1-B2-C12;
A1-B2-C13; A1-B2-C14; A1-B2-C15; A1-B2-C16; A1-B2-C17; A1-B2-C18;
A1-B2-C19; A1-B2-C20; A1-B2-C21; A1-B2-C22; A1-B2-C23; A1-B2-C24;
A1-B2-C25; A1-B2-C26; A1-B2-C27; A2-B2-C1; A2-B2-C2; A2-B2-C3;
A2-B2-C4; A2-B2-C5; A2-B2-C6; A2-B2-C7; A2-B2-C8; A2-B2-C9;
A2-B2-C10; A2-B2-C11; A2-B2-C12; A2-B2-C13; A2-B2-C14; A2-B2-C15;
A2-B2-C16; A2-B2-C17; A2-B2-C18; A2-B2-C19; A2-B2-C20; A2-B2-C21;
A2-B2-C22; A2-B2-C23; A2-B2-C24; A2-B2-C25; A2-B2-C26; A2-B2-C27;
A3-B2-C1; A3-B2-C2; A3-B2-C3; A3-B2-C4; A3-B2-C5; A3-B2-C6;
A3-B2-C7; A3-B2-C8; A3-B2-C9; A3-B2-C10; A3-B2-C11; A3-B2-C12;
A3-B2-C13; A3-B2-C14; A3-B2-C15; A3-B2-C16; A3-B2-C17; A3-B2-C18;
A3-B2-C19; A3-B2-C20; A3-B2-C21; A3-B2-C22; A3-B2-C23; A3-B2-C24;
A3-B2-C25; A3-B2-C26; A3-B2-C27; A4-B2-C1; A4-B2-C2; A4-B2-C3;
A4-B2-C4; A4-B2-C5; A4-B2-C6; A4-B2-C7; A4-B2-C8; A4-B2-C9;
A4-B2-C10; A4-B2-C11; A4-B2-C12; A4-B2-C13; A4-B2-C14; A4-B2-C15;
A4-B2-C16; A4-B2-C17; A4-B2-C18; A4-B2-C19; A4-B2-C20; A4-B2-C21;
A4-B2-C22; A4-B2-C23; A4-B2-C24; A4-B2-C25; A4-B2-C26; A4-B2-C27;
A5-B2-C1; A5-B2-C2; A5-B2-C3; A5-B2-C4; A5-B2-C5; A5-B2-C6;

A5-B2-C7;	A5-B2-C8;	A5-B2-C9;	A5-B2-C10;	A5-B2-C11;	A5-B2-C12;
A5-B2-C13;	A5-B2-C14;	A5-B2-C15;	A5-B2-C16;	A5-B2-C17;	A5-B2-C18;
A5-B2-C19;	A5-B2-C20;	A5-B2-C21;	A5-B2-C22;	A5-B2-C23;	A5-B2-C24;
A5-B2-C25;	A5-B2-C26;	A5-B2-C27;	A6-B2-C1;	A6-B2-C2;	A6-B2-C3;
A6-B2-C4;	A6-B2-C5;	A6-B2-C6;	A6-B2-C7;	A6-B2-C8;	A6-B2-C9;
A6-B2-C10;	A6-B2-C11;	A6-B2-C12;	A6-B2-C13;	A6-B2-C14;	A6-B2-C15;
A6-B2-C16;	A6-B2-C17;	A6-B2-C18;	A6-B2-C19;	A6-B2-C20;	A6-B2-C21;
A6-B2-C22;	A6-B2-C23;	A6-B2-C24;	A6-B2-C25;	A6-B2-C26;	A6-B2-C27;
A7-B2-C1;	A7-B2-C2;	A7-B2-C3;	A7-B2-C4;	A7-B2-C5;	A7-B2-C6;
A7-B2-C7;	A7-B2-C8;	A7-B2-C9;	A7-B2-C10;	A7-B2-C11;	A7-B2-C12;
A7-B2-C13;	A7-B2-C14;	A7-B2-C15;	A7-B2-C16;	A7-B2-C17;	A7-B2-C18;
A7-B2-C19;	A7-B2-C20;	A7-B2-C21;	A7-B2-C22;	A7-B2-C23;	A7-B2-C24;
A7-B2-C25;	A7-B2-C26;	A7-B2-C27;	A8-B2-C1;	A8-B2-C2;	A8-B2-C3;
A8-B2-C4;	A8-B2-C5;	A8-B2-C6;	A8-B2-C7;	A8-B2-C8;	A8-B2-C9;
A8-B2-C10;	A8-B2-C11;	A8-B2-C12;	A8-B2-C13;	A8-B2-C14;	A8-B2-C15;
A8-B2-C16;	A8-B2-C17;	A8-B2-C18;	A8-B2-C19;	A8-B2-C20;	A8-B2-C21;
A8-B2-C22;	A8-B2-C23;	A8-B2-C24;	A8-B2-C25;	A8-B2-C26;	A8-B2-C27;
A9-B2-C1;	A9-B2-C2;	A9-B2-C3;	A9-B2-C4;	A9-B2-C5;	A9-B2-C6;
A9-B2-C7;	A9-B2-C8;	A9-B2-C9;	A9-B2-C10;	A9-B2-C11;	A9-B2-C12;
A9-B2-C13;	A9-B2-C14;	A9-B2-C15;	A9-B2-C16;	A9-B2-C17;	A9-B2-C18;
A9-B2-C19;	A9-B2-C20;	A9-B2-C21;	A9-B2-C22;	A9-B2-C23;	A9-B2-C24;
A9-B2-C25;	A9-B2-C26;	A9-B2-C27;	A10-B2-C1;	A10-B2-C2;	A10-B2-C3;
A10-B2-C4;	A10-B2-C5;	A10-B2-C6;	A10-B2-C7;	A10-B2-C8;	A10-B2-C9;
A10-B2-C10;	A10-B2-C11;	A10-B2-C12;	A10-B2-C13;	A10-B2-C14;	A10-B2-C15;
A10-B2-C16;	A10-B2-C17;	A10-B2-C18;	A10-B2-C19;	A10-B2-C20;	A10-B2-C21;
A10-B2-C22;	A10-B2-C23;	A10-B2-C24;	A10-B2-C25;	A10-B2-C26;	A10-B2-C27;
A11-B2-C1;	A11-B2-C2	A11-B2-C3;	A11-B2-C4;	A11-B2-C5;	A11-B2-C6;
A11-B2-C7;	A11-B2-C8;	A11-B2-C9;	A11-B2-C10;	A11-B2-C11;	A11-B2-C12;
A11-B2-C13;	A11-B2-C14;	A11-B2-C15;	A11-B2-C16;	A11-B2-C17;	A11-B2-C18;
A11-B2-C19;	A11-B2-C20;	A11-B2-C21;	A11-B2-C22;	A11-B2-C23;	A11-B2-C24;
A11-B2-C25;	A11-B2-C26;	A11-B2-C27;	A12-B2-C1;	A12-B2-C2;	A12-B2-C3;
A12-B2-C4;	A12-B2-C5;	A12-B2-C6;	A12-B2-C7;	A12-B2-C8;	A12-B2-C9;
A12-B2-C10;	A12-B2-C11;	A12-B2-C12;	A12-B2-C13;	A12-B2-C14;	A12-B2-C15;
A12-B2-C16;	A12-B2-C17;	A12-B2-C18;	A12-B2-C19;	A12-B2-C20;	A12-B2-C21;
A12-B2-C22;	A12-B2-C23;	A12-B2-C24;	A12-B2-C25;	A12-B2-C26;	A12-B2-C27;

A13-B2-C1; A13-B2-C2; A13-B2-C3; A13-B2-C4; A13-B2-C5; A13-B2-C6;
A13-B2-C7; A13-B2-C8; A13-B2-C9; A13-B2-C10; A13-B2-C11; A13-B2-C12;
A13-B2-C13; A13-B2-C14; A13-B2-C15; A13-B2-C16; A13-B2-C17; A13-B2-C18;
A13-B2-C19; A13-B2-C20; A13-B2-C21; A13-B2-C22; A13-B2-C23; A13-B2-C24;
A13-B2-C25; A13-B2-C26; A13-B2-C27; A14-B2-C1; A14-B2-C2; A14-B2-C3;
A14-B2-C4; A14-B2-C5; A14-B2-C6; A14-B2-C7; A14-B2-C8; A14-B2-C9;
A14-B2-C10; A14-B2-C11; A14-B2-C12; A14-B2-C13; A14-B2-C14; A14-B2-C15;
A14-B2-C16; A14-B2-C17; A14-B2-C18; A14-B2-C19; A14-B2-C20; A14-B2-C21;
A14-B2-C22; A14-B2-C23; A14-B2-C24; A14-B2-C25; A14-B2-C26; A14-B2-C27;
A15-B2-C1; A15-B2-C2; A15-B2-C3; A15-B2-C4; A15-B2-C5; A15-B2-C6;
A15-B2-C7; A15-B2-C8; A15-B2-C9; A15-B2-C10; A15-B2-C11; A15-B2-C12;
A15-B2-C13; A15-B2-C14; A15-B2-C15; A15-B2-C16; A15-B2-C17; A15-B2-C18;
A15-B2-C19; A15-B2-C20; A15-B2-C21; A15-B2-C22; A15-B2-C23; A15-B2-C24;
A15-B2-C25; A15-B2-C26; A15-B2-C27; A16-B2-C1; A16-B2-C2; A16-B2-C3;
A16-B2-C4; A16-B2-C5; A16-B2-C6; A16-B2-C7; A16-B2-C8; A16-B2-C9;
A16-B2-C10; A16-B2-C11; A16-B2-C12; A16-B2-C13; A16-B2-C14; A16-B2-C15;
A16-B2-C16; A16-B2-C17; A16-B2-C18; A16-B2-C19; A16-B2-C20; A16-B2-C21;
A16-B2-C22; A16-B2-C23; A16-B2-C24; A16-B2-C25; A16-B2-C26; A16-B2-C27;
A17-B2-C1; A17-B2-C2; A17-B2-C3; A17-B2-C4; A17-B2-C5; A17-B2-C6;
A17-B2-C7; A17-B2-C8; A17-B2-C9; A17-B2-C10; A17-B2-C11; A17-B2-C12;
A17-B2-C13; A17-B2-C14; A17-B2-C15; A17-B2-C16; A17-B2-C17; A17-B2-C18;
A17-B2-C19; A17-B2-C20; A17-B2-C21; A17-B2-C22; A17-B2-C23; A17-B2-C24;
A17-B2-C25; A17-B2-C26; A17-B2-C27; A18-B2-C1; A18-B2-C2; A18-B2-C3;
A18-B2-C4; A18-B2-C5; A18-B2-C6; A18-B2-C7; A18-B2-C8; A18-B2-C9;
A18-B2-C10; A18-B2-C11; A18-B2-C12; A18-B2-C13; A18-B2-C14; A18-B2-C15;
A18-B2-C16; A18-B2-C17; A18-B2-C18; A18-B2-C19; A18-B2-C20; A18-B2-C21;
A18-B2-C22; A18-B2-C23; A18-B2-C24; A18-B2-C25; A18-B2-C26; A18-B2-C27;
A19-B2-C1; A19-B2-C2; A19-B2-C3; A19-B2-C4; A19-B2-C5; A19-B2-C6;
A19-B2-C7; A19-B2-C8; A19-B2-C9; A19-B2-C10; A19-B2-C11; A19-B2-C12;
A19-B2-C13; A19-B2-C14; A19-B2-C15; A19-B2-C16; A19-B2-C17; A19-B2-C18;
A19-B2-C19; A19-B2-C20; A19-B2-C21; A19-B2-C22; A19-B2-C23; A19-B2-C24;
A19-B2-C25; A19-B2-C26; A19-B2-C27; A20-B2-C1; A20-B2-C2; A20-B2-C3;
A20-B2-C4; A20-B2-C5; A20-B2-C6; A20-B2-C7; A20-B2-C8; A20-B2-C9;
A20-B2-C10; A20-B2-C11; A20-B2-C12; A20-B2-C13; A20-B2-C14; A20-B2-C15;
A20-B2-C16; A20-B2-C17; A20-B2-C18; A20-B2-C19; A20-B2-C20; A20-B2-C21;

A20-B2-C22; A20-B2-C23; A20-B2-C24; A20-B2-C25; A20-B2-C26; A20-B2-C27;
A21-B2-C1; A21-B2-C2; A21-B2-C3; A21-B2-C4; A21-B2-C5; A21-B2-C6;
A21-B2-C7; A21-B2-C8; A21-B2-C9; A21-B2-C10; A21-B2-C11; A21-B2-C12;
A21-B2-C13; A21-B2-C14; A21-B2-C15; A21-B2-C16; A21-B2-C17; A21-B2-C18;
A21-B2-C19; A21-B2-C20; A21-B2-C21; A21-B2-C22; A21-B2-C23; A21-B2-C24;
A21-B2-C25; A21-B2-C26; A21-B2-C27; A22-B2-C1; A22-B2-C2; A22-B2-C3;
A22-B2-C4; A22-B2-C5; A22-B2-C6; A22-B2-C7; A22-B2-C8; A22-B2-C9;
A22-B2-C10; A22-B2-C11; A22-B2-C12; A22-B2-C13; A22-B2-C14; A22-B2-C15;
A22-B2-C16; A22-B2-C17; A22-B2-C18; A22-B2-C19; A22-B2-C20; A22-B2-C21;
A22-B2-C22; A22-B2-C23; A22-B2-C24; A22-B2-C25; A22-B2-C26; A22-B2-C27;
A23-B2-C1; A23-B2-C2; A23-B2-C3; A23-B2-C4; A23-B2-C5; A23-B2-C6;
A23-B2-C7; A23-B2-C8; A23-B2-C9; A23-B2-C10; A23-B2-C11; A23-B2-C12;
A23-B2-C13; A23-B2-C14; A23-B2-C15; A23-B2-C16; A23-B2-C17; A23-B2-C18;
A23-B2-C19; A23-B2-C20; A23-B2-C21; A23-B2-C22; A23-B2-C23; A23-B2-C24;
A23-B2-C25; A23-B2-C26; A23-B2-C27; A24-B2-C1; A24-B2-C2; A24-B2-C3;
A24-B2-C4; A24-B2-C5; A24-B2-C6; A24-B2-C7; A24-B2-C8; A24-B2-C9;
A24-B2-C10; A24-B2-C11; A24-B2-C12; A24-B2-C13; A24-B2-C14; A24-B2-C15;
A24-B2-C16; A24-B2-C17; A24-B2-C18; A24-B2-C19; A24-B2-C20; A24-B2-C21;
A24-B2-C22; A24-B2-C23; A24-B2-C24; A24-B2-C25; A24-B2-C26; A24-B2-C27;
A25-B2-C1; A25-B2-C2; A25-B2-C3; A25-B2-C4; A25-B2-C5; A25-B2-C6;
A25-B2-C7; A25-B2-C8; A25-B2-C9; A25-B2-C10; A25-B2-C11; A25-B2-C12;
A25-B2-C13; A25-B2-C14; A25-B2-C15; A25-B2-C16; A25-B2-C17; A25-B2-C18;
A25-B2-C19; A25-B2-C20; A25-B2-C21; A25-B2-C22; A25-B2-C23; A25-B2-C24;
A25-B2-C25; A25-B2-C26; A25-B2-C27; A26-B2-C1; A26-B2-C2; A26-B2-C3;
A26-B2-C4; A26-B2-C5; A26-B2-C6; A26-B2-C7; A26-B2-C8; A26-B2-C9;
A26-B2-C10; A26-B2-C11; A26-B2-C12; A26-B2-C13; A26-B2-C14; A26-B2-C15;
A26-B2-C16; A26-B2-C17; A26-B2-C18; A26-B2-C19; A26-B2-C20; A26-B2-C21;
A26-B2-C22; A26-B2-C23; A26-B2-C24; A26-B2-C25; A26-B2-C26; A26-B2-C27;
A27-B2-C1; A27-B2-C2; A27-B2-C3; A27-B2-C4; A27-B2-C5; A27-B2-C6;
A27-B2-C7; A27-B2-C8; A27-B2-C9; A27-B2-C10; A27-B2-C11; A27-B2-C12;
A27-B2-C13; A27-B2-C14; A27-B2-C15; A27-B2-C16; A27-B2-C17; A27-B2-C18;
A27-B2-C19; A27-B2-C20; A27-B2-C21; A27-B2-C22; A27-B2-C23; A27-B2-C24;
A27-B2-C25; A27-B2-C26; A27-B2-C27; A28-B2-C1; A28-B2-C2; A28-B2-C3;
A28-B2-C4; A28-B2-C5; A28-B2-C6; A28-B2-C7; A28-B2-C8; A28-B2-C9;
A28-B2-C10; A28-B2-C11; A28-B2-C12; A28-B2-C13; A28-B2-C14; A28-B2-C15;

A28-B2-C16; A28-B2-C17; A28-B2-C18; A28-B2-C19; A28-B2-C20; A28-B2-C21;
A28-B2-C22; A28-B2-C23; A28-B2-C24; A28-B2-C25; A28-B2-C26; A28-B2-C27;
A29-B2-C1; A29-B2-C2; A29-B2-C3; A29-B2-C4; A29-B2-C5; A29-B2-C6;
A29-B2-C7; A29-B2-C8; A29-B2-C9; A29-B2-C10; A29-B2-C11; A29-B2-C12;
A29-B2-C13; A29-B2-C14; A29-B2-C15; A29-B2-C16; A29-B2-C17; A29-B2-C18;
A29-B2-C19; A29-B2-C20; A29-B2-C21; A29-B2-C22; A29-B2-C23; A29-B2-C24;
A29-B2-C25; A29-B2-C26; A29-B2-C27; A30-B2-C1; A30-B2-C2; A30-B2-C3;
A30-B2-C4; A30-B2-C5; A30-B2-C6; A30-B2-C7; A30-B2-C8 A30-B2-C9;
A30-B2-C10; A30-B2-C11; A30-B2-C12; A30-B2-C13; A30-B2-C14; A30-B2-C15;
A30-B2-C16; A30-B2-C17; A30-B2-C18; A30-B2-C19; A30-B2-C20; A30-B2-C21;
A30-B2-C22; A30-B2-C23; A30-B2-C24; A30-B2-C25; A30-B2-C26; A30-B2-C27;
A31-B2-C1; A31-B2-C2; A31-B2-C3; A31-B2-C4; A31-B2-C5; A31-B2-C6;
A31-B2-C7; A31-B2-C8; A31-B2-C9; A31-B2-C10; A31-B2-C11; A31-B2-C12;
A31-B2-C13; A31-B2-C14; A31-B2-C15; A31-B2-C16; A31-B2-C17; A31-B2-C18;
A31-B2-C19; A31-B2-C20; A31-B2-C21; A31-B2-C22; A31-B2-C23; A31-B2-C24;
A31-B2-C25; A31-B2-C26; A31-B2-C27; A32-B2-C1; A32-B2-C2; A32-B2-C3;
A32-B2-C4; A32-B2-C5; A32-B2-C6; A32-B2-C7; A32-B2-C8; A32-B2-C9;
A32-B2-C10; A32-B2-C11; A32-B2-C12; A32-B2-C13; A32-B2-C14; A32-B2-C15;
A32-B2-C16; A32-B2-C17; A32-B2-C18; A32-B2-C19; A32-B2-C20; A32-B2-C21;
A32-B2-C22; A32-B2-C23; A32-B2-C24; A32-B2-C25; A32-B2-C26; A32-B2-C27;
A33-B2-C1; A33-B2-C2; A33-B2-C3; A33-B2-C4; A33-B2-C5; A33-B2-C6;
A33-B2-C7; A33-B2-C8; A33-B2-C9; A33-B2-C10; A33-B2-C11; A33-B2-C12;
A33-B2-C13; A33-B2-C14; A33-B2-C15; A33-B2-C16; A33-B2-C17; A33-B2-C18;
A33-B2-C19; A33-B2-C20; A33-B2-C21; A33-B2-C22; A33-B2-C23; A33-B2-C24;
A33-B2-C25; A33-B2-C26; A33-B2-C27; A34-B2-C1; A34-B2-C2; A34-B2-C3;
A34-B2-C4; A34-B2-C5; A34-B2-C6; A34-B2-C7; A34-B2-C8; A34-B2-C9
A34-B2-C10; A34-B2-C11; A34-B2-C12; A34-B2-C13; A34-B2-C14; A34-B2-C15;
A34-B2-C16; A34-B2-C17; A34-B2-C18; A34-B2-C19; A34-B2-C20; A34-B2-C21;
A34-B2-C22; A34-B2-C23; A34-B2-C24; A34-B2-C25; A34-B2-C26; A34-B2-C27;
A35-B2-C1; A35-B2-C2; A35-B2-C3; A35-B2-C4; A35-B2-C5; A35-B2-C6;
A35-B2-C7; A35-B2-C8; A35-B2-C9; A35-B2-C10; A35-B2-C11; A35-B2-C12;
A35-B2-C13; A35-B2-C14; A35-B2-C15; A35-B2-C16; A35-B2-C17; A35-B2-C18;
A35-B2-C19; A35-B2-C20; A35-B2-C21; A35-B2-C22; A35-B2-C23; A35-B2-C24;
A35-B2-C25; A35-B2-C26; A35-B2-C27; A36-B2-C1; A36-B2-C2; A36-B2-C3;
A36-B2-C4; A36-B2-C5; A36-B2-C6; A36-B2-C7; A36-B2-C8; A36-B2-C9;

A36-B2-C10; A36-B2-C11; A36-B2-C12; A36-B2-C13; A36-B2-C14; A36-B2-C15;
A36-B2-C16; A36-B2-C17; A36-B2-C18; A36-B2-C19; A36-B2-C20; A36-B2-C21;
A36-B2-C22; A36-B2-C23; A36-B2-C24; A36-B2-C25; A36-B2-C26; A36-B2-C27;
A1-B3-C1; A1-B3-C2; A1-B3-C3; A1-B3-C4; A1-B3-C5; A1-B3-C6;
A1-B3-C7; A1-B3-C8; A1-B3-C9; A1-B3-C10; A1-B3-C11; A1-B3-C12;
A1-B3-C13; A1-B3-C14; A1-B3-C15; A1-B3-C16; A1-B3-C17; A1-B3-C18;
A1-B3-C19; A1-B3-C20; A1-B3-C21; A1-B3-C22; A1-B3-C23; A1-B3-C24;
A1-B3-C25; A1-B3-C26; A1-B3-C27; A2-B3-C1; A2-B3-C2; A2-B3-C3;
A2-B3-C4; A2-B3-C5; A2-B3-C6; A2-B3-C7; A2-B3-C8; A2-B3-C9;
A2-B3-C10; A2-B3-C11; A2-B3-C12; A2-B3-C13; A2-B3-C14; A2-B3-C15;
A2-B3-C16; A2-B3-C17; A2-B3-C18; A2-B3-C19; A2-B3-C20; A2-B3-C21;
A2-B3-C22; A2-B3-C23; A2-B3-C24; A2-B3-C25; A2-B3-C26; A2-B3-C27;
A3-B3-C1; A3-B3-C2; A3-B3-C3; A3-B3-C4; A3-B3-C5; A3-B3-C6;
A3-B3-C7; A3-B3-C8; A3-B3-C9; A3-B3-C10; A3-B3-C11; A3-B3-C12;
A3-B3-C13; A3-B3-C14; A3-B3-C15; A3-B3-C16; A3-B3-C17; A3-B3-C18;
A3-B3-C19; A3-B3-C20; A3-B3-C21; A3-B3-C22; A3-B3-C23; A3-B3-C24;
A3-B3-C25; A3-B3-C26; A3-B3-C27; A4-B3-C1; A4-B3-C2; A4-B3-C3;
A4-B3-C4; A4-B3-C5; A4-B3-C6; A4-B3-C7; A4-B3-C8; A4-B3-C9;
A4-B3-C10; A4-B3-C11; A4-B3-C12; A4-B3-C13; A4-B3-C14; A4-B3-C15;
A4-B3-C16; A4-B3-C17; A4-B3-C18; A4-B3-C19; A4-B3-C20; A4-B3-C21;
A4-B3-C22; A4-B3-C23; A4-B3-C24; A4-B3-C25; A4-B3-C26; A4-B3-C27;
A5-B3-C1; A5-B3-C2; A5-B3-C3; A5-B3-C4; A5-B3-C5; A5-B3-C6;
A5-B3-C7; A5-B3-C8; A5-B3-C9; A5-B3-C10; A5-B3-C11; A5-B3-C12;
A5-B3-C13; A5-B3-C14; A5-B3-C15; A5-B3-C16; A5-B3-C17; A5-B3-C18;
A5-B3-C19; A5-B3-C20; A5-B3-C21; A5-B3-C22; A5-B3-C23; A5-B3-C24;
A5-B3-C25; A5-B3-C26; A5-B3-C27; A6-B3-C1; A6-B3-C2; A6-B3-C3;
A6-B3-C4; A6-B3-C5; A6-B3-C6; A6-B3-C7; A6-B3-C8; A6-B3-C9;
A6-B3-C10; A6-B3-C11; A6-B3-C12; A6-B3-C13; A6-B3-C14; A6-B3-C15;
A6-B3-C16; A6-B3-C17; A6-B3-C18; A6-B3-C19; A6-B3-C20; A6-B3-C21;
A6-B3-C22; A6-B3-C23; A6-B3-C24; A6-B3-C25; A6-B3-C26; A6-B3-C27;
A7-B3-C1; A7-B3-C2; A7-B3-C3; A7-B3-C4; A7-B3-C5; A7-B3-C6;
A7-B3-C7; A7-B3-C8; A7-B3-C9; A7-B3-C10; A7-B3-C11; A7-B3-C12;
A7-B3-C13; A7-B3-C14; A7-B3-C15; A7-B3-C16; A7-B3-C17; A7-B3-C18;
A7-B3-C19; A7-B3-C20; A7-B3-C21; A7-B3-C22; A7-B3-C23; A7-B3-C24;
A7-B3-C25; A7-B3-C26; A7-B3-C27; A8-B3-C1; A8-B3-C2; A8-B3-C3;

A8-B3-C4;	A8-B3-C5;	A8-B3-C6;	A8-B3-C7;	A8-B3-C8;	A8-B3-C9;
A8-B3-C10;	A8-B3-C11;	A8-B3-C12;	A8-B3-C13;	A8-B3-C14;	A8-B3-C15;
A8-B3-C16;	A8-B3-C17;	A8-B3-C18;	A8-B3-C19;	A8-B3-C20;	A8-B3-C21;
A8-B3-C22;	A8-B3-C23;	A8-B3-C24;	A8-B3-C25;	A8-B3-C26;	A8-B3-C27;
A9-B3-C1;	A9-B3-C2;	A9-B3-C3;	A9-B3-C4;	A9-B3-C5;	A9-B3-C6;
A9-B3-C7;	A9-B3-C8;	A9-B3-C9;	A9-B3-C10;	A9-B3-C11;	A9-B3-C12;
A9-B3-C13;	A9-B3-C14;	A9-B3-C15;	A9-B3-C16;	A9-B3-C17;	A9-B3-C18;
A9-B3-C19;	A9-B3-C20;	A9-B3-C21;	A9-B3-C22;	A9-B3-C23;	A9-B3-C24;
A9-B3-C25;	A9-B3-C26;	A9-B3-C27;	A10-B3-C1;	A10-B3-C2;	A10-B3-C3;
A10-B3-C4;	A10-B3-C5;	A10-B3-C6;	A10-B3-C7;	A10-B3-C8;	A10-B3-C9;
A10-B3-C10;	A10-B3-C11;	A10-B3-C12;	A10-B3-C13;	A10-B3-C14;	A10-B3-C15;
A10-B3-C16;	A10-B3-C17;	A10-B3-C18;	A10-B3-C19;	A10-B3-C20;	A10-B3-C21;
A10-B3-C22;	A10-B3-C23;	A10-B3-C24;	A10-B3-C25;	A10-B3-C26;	A10-B3-C27;
A11-B3-C1;	A11-B3-C2;	A11-B3-C3;	A11-B3-C4;	A11-B3-C5;	A11-B3-C6;
A11-B3-C7;	A11-B3-C8;	A11-B3-C9;	A11-B3-C10;	A11-B3-C11;	A11-B3-C12;
A11-B3-C13;	A11-B3-C14;	A11-B3-C15;	A11-B3-C16;	A11-B3-C17;	A11-B3-C18;
A11-B3-C19;	A11-B3-C20;	A11-B3-C21;	A11-B3-C22;	A11-B3-C23;	A11-B3-C24;
A11-B3-C25;	A11-B3-C26;	A12-B3-C27;	A12-B3-C1;	A12-B3-C2;	A12-B3-C3;
A12-B3-C4;	A12-B3-C5;	A12-B3-C6;	A12-B3-C7;	A12-B3-C8;	A12-B3-C9;
A12-B3-C10;	A12-B3-C11;	A12-B3-C12;	A12-B3-C13;	A12-B3-C14;	A12-B3-C15;
A12-B3-C16;	A12-B3-C17;	A12-B3-C18;	A12-B3-C19;	A12-B3-C20;	A12-B3-C21;
A12-B3-C22;	A12-B3-C23;	A12-B3-C24;	A12-B3-C25;	A12-B3-C26;	A13-B3-C27;
A13-B3-C1;	A13-B3-C2;	A13-B3-C3;	A13-B3-C4;	A13-B3-C5;	A13-B3-C6;
A13-B3-C7;	A13-B3-C8;	A13-B3-C9;	A13-B3-C10;	A13-B3-C11;	A13-B3-C12;
A13-B3-C13;	A13-B3-C14;	A13-B3-C15;	A13-B3-C16;	A13-B3-C17;	A13-B3-C18;
A13-B3-C19;	A13-B3-C20;	A13-B3-C21;	A13-B3-C22;	A13-B3-C23;	A13-B3-C24;
A13-B3-C25;	A13-B3-C26;	A14-B3-C27;	A14-B3-C1;	A14-B3-C2;	A14-B3-C3;
A14-B3-C4;	A14-B3-C5;	A14-B3-C6;	A14-B3-C7;	A14-B3-C8;	A14-B3-C9;
A14-B3-C10;	A14-B3-C11;	A14-B3-C12;	A14-B3-C13;	A14-B3-C14;	A14-B3-C15;
A14-B3-C16;	A14-B3-C17;	A14-B3-C18;	A14-B3-C19;	A14-B3-C20;	A14-B3-C21;
A14-B3-C22;	A14-B3-C23;	A14-B3-C24;	A14-B3-C25;	A14-B3-C26;	A14-B3-C27;
A15-B3-C1;	A15-B3-C2;	A15-B3-C3;	A15-B3-C4;	A15-B3-C5;	A15-B3-C6;
A15-B3-C7;	A15-B3-C8;	A15-B3-C9;	A15-B3-C10;	A15-B3-C11;	A15-B3-C12;
A15-B3-C13;	A15-B3-C14;	A15-B3-C15;	A15-B3-C16;	A15-B3-C17;	A15-B3-C18;
A15-B3-C19;	A15-B3-C20;	A15-B3-C21;	A15-B3-C22;	A15-B3-C23;	A15-B3-C24;

A15-B3-C25; A15-B3-C26; A15-B3-C27; A16-B3-C1; A16-B3-C2; A16-B3-C3;
A16-B3-C4; A16-B3-C5; A16-B3-C6; A16-B3-C7; A16-B3-C8; A16-B3-C9;
A16-B3-C10; A16-B3-C11; A16-B3-C12; A16-B3-C13; A16-B3-C14; A16-B3-C15;
A16-B3-C16; A16-B3-C17; A16-B3-C18; A16-B3-C19; A16-B3-C20; A16-B3-C21;
A16-B3-C22; A16-B3-C23; A16-B3-C24; A16-B3-C25; A16-B3-C26; A16-B3-C27;
A17-B3-C1; A17-B3-C2; A17-B3-C3; A17-B3-C4; A17-B3-C5; A17-B3-C6;
A17-B3-C7; A17-B3-C8; A17-B3-C9; A17-B3-C10; A17-B3-C11; A17-B3-C12;
A17-B3-C13; A17-B3-C14; A17-B3-C15; A17-B3-C16; A17-B3-C17; A17-B3-C18;
A17-B3-C19; A17-B3-C20; A17-B3-C21; A17-B3-C22; A17-B3-C23; A17-B3-C24;
A17-B3-C25; A17-B3-C26; A17-B3-C27; A18-B3-C1; A18-B3-C2; A18-B3-C3;
A18-B3-C4; A18-B3-C5; A18-B3-C6; A18-B3-C7; A18-B3-C8; A18-B3-C9;
A18-B3-C10; A18-B3-C11; A18-B3-C12; A18-B3-C13; A18-B3-C14; A18-B3-C15;
A18-B3-C16; A18-B3-C17; A18-B3-C18; A18-B3-C19; A18-B3-C20; A18-B3-C21;
A18-B3-C22; A18-B3-C23; A18-B3-C24; A18-B3-C25; A18-B3-C26; A19-B3-C27;
A19-B3-C1; A19-B3-C2; A19-B3-C3; A19-B3-C4; A19-B3-C5; A19-B3-C6;
A19-B3-C7; A19-B3-C8; A19-B3-C9; A19-B3-C10; A19-B3-C11; A19-B3-C12;
A19-B3-C13; A19-B3-C14; A19-B3-C15; A19-B3-C16; A19-B3-C17; A19-B3-C18;
A19-B3-C19; A19-B3-C20; A19-B3-C21; A19-B3-C22; A19-B3-C23; A19-B3-C24;
A19-B3-C25; A19-B3-C26; A19-B3-C27; A20-B3-C1; A20-B3-C2; A20-B3-C3;
A20-B3-C4; A20-B3-C5; A20-B3-C6; A20-B3-C7; A20-B3-C8; A20-B3-C9;
A20-B3-C10; A20-B3-C11; A20-B3-C12; A20-B3-C13; A20-B3-C14; A20-B3-C15;
A20-B3-C16; A20-B3-C17; A20-B3-C18; A20-B3-C19; A20-B3-C20; A20-B3-C21;
A20-B3-C22; A20-B3-C23; A20-B3-C24; A20-B3-C25; A20-B3-C26; A20-B3-C27;
A21-B3-C1; A21-B3-C2; A21-B3-C3; A21-B3-C4; A21-B3-C5; A21-B3-C6;
A21-B3-C7; A21-B3-C8; A21-B3-C9; A21-B3-C10; A21-B3-C11; A21-B3-C12;
A21-B3-C13; A21-B3-C14; A21-B3-C15; A21-B3-C16; A21-B3-C17; A21-B3-C18;
A21-B3-C19; A21-B3-C20; A21-B3-C21; A21-B3-C22; A21-B3-C23; A21-B3-C24;
A21-B3-C25; A21-B3-C26; A21-B3-C27; A22-B3-C1; A22-B3-C2; A22-B3-C3;
A22-B3-C4; A22-B3-C5; A22-B3-C6; A22-B3-C7; A22-B3-C8; A22-B3-C9;
A22-B3-C10; A22-B3-C11; A22-B3-C12; A22-B3-C13; A22-B3-C14; A22-B3-C15;
A22-B3-C16; A22-B3-C17; A22-B3-C18; A22-B3-C19; A22-B3-C20; A22-B3-C21;
A22-B3-C22; A22-B3-C23; A22-B3-C24; A22-B3-C25; A22-B3-C26; A22-B3-C27;
A23-B3-C1; A23-B3-C2; A23-B3-C3; A23-B3-C4; A23-B3-C5; A23-B3-C6;
A23-B3-C7; A23-B3-C8; A23-B3-C9; A23-B3-C10; A23-B3-C11; A23-B3-C12;
A23-B3-C13; A23-B3-C14; A23-B3-C15; A23-B3-C16; A23-B3-C17; A23-B3-C18;

A23-B3-C19; A23-B3-C20; A23-B3-C21; A23-B3-C22; A23-B3-C23; A23-B3-C24;
A23-B3-C25; A23-B3-C26; A23-B3-C27; A24-B3-C1; A24-B3-C2; A24-B3-C3;
A24-B3-C4; A24-B3-C5; A24-B3-C6; A24-B3-C7; A24-B3-C8; A24-B3-C9;
A24-B3-C10; A24-B3-C11; A24-B3-C12; A24-B3-C13; A24-B3-C14; A24-B3-C15;
A24-B3-C16; A24-B3-C17; A24-B3-C18; A24-B3-C19; A24-B3-C20; A24-B3-C21;
A24-B3-C22; A24-B3-C23; A24-B3-C24; A24-B3-C25; A24-B3-C26; A24-B3-C27;
A25-B3-C1; A25-B3-C2; A25-B3-C3; A25-B3-C4; A25-B3-C5; A25-B3-C6;
A25-B3-C7; A25-B3-C8; A25-B3-C9; A25-B3-C10; A25-B3-C11; A25-B3-C12;
A25-B3-C13; A25-B3-C14; A25-B3-C15; A25-B3-C16; A25-B3-C17; A25-B3-C18;
A25-B3-C19; A25-B3-C20; A25-B3-C21; A25-B3-C22; A25-B3-C23; A25-B3-C24;
A25-B3-C25; A25-B3-C26; A25-B3-C27; A26-B3-C1; A26-B3-C2; A26-B3-C3;
A26-B3-C4; A26-B3-C5; A26-B3-C6; A26-B3-C7; A26-B3-C8; A26-B3-C9;
A26-B3-C10; A26-B3-C11; A26-B3-C12; A26-B3-C13; A26-B3-C14; A26-B3-C15;
A26-B3-C16; A26-B3-C17; A26-B3-C18; A26-B3-C19; A26-B3-C20; A26-B3-C21;
A26-B3-C22; A26-B3-C23; A26-B3-C24; A26-B3-C25; A26-B3-C26; A26-B3-C27;
A27-B3-C1; A27-B3-C2; A27-B3-C3; A27-B3-C4; A27-B3-C5; A27-B3-C6;
A27-B3-C7; A27-B3-C8; A27-B3-C9; A27-B3-C10; A27-B3-C11; A27-B3-C12;
A27-B3-C13; A27-B3-C14; A27-B3-C15; A27-B3-C16; A27-B3-C17; A27-B3-C18;
A27-B3-C19; A27-B3-C20; A27-B3-C21; A27-B3-C22; A27-B3-C23; A27-B3-C24;
A27-B3-C25; A27-B3-C26; A27-B3-C27; A28-B3-C1; A28-B3-C2; A28-B3-C3;
A28-B3-C4; A28-B3-C5; A28-B3-C6; A28-B3-C7; A28-B3-C8; A28-B3-C9;
A28-B3-C10; A28-B3-C11; A28-B3-C12; A28-B3-C13; A28-B3-C14; A28-B3-C15;
A28-B3-C16; A28-B3-C17; A28-B3-C18; A28-B3-C19; A28-B3-C20; A28-B3-C21;
A28-B3-C22; A28-B3-C23; A28-B3-C24; A28-B3-C25; A28-B3-C26; A28-B3-C27;
A29-B3-C1; A29-B3-C2; A29-B3-C3; A29-B3-C4; A29-B3-C5; A29-B3-C6;
A29-B3-C7; A29-B3-C8; A29-B3-C9; A29-B3-C10; A29-B3-C11; A29-B3-C12;
A29-B3-C13; A29-B3-C14; A29-B3-C15; A29-B3-C16; A29-B3-C17; A29-B3-C18;
A29-B3-C19; A29-B3-C20; A29-B3-C21; A29-B3-C22; A29-B3-C23; A29-B3-C24;
A29-B3-C25; A29-B3-C26; A29-B3-C27; A30-B3-C1; A30-B3-C2; A30-B3-C3;
A30-B3-C4; A30-B3-C5; A30-B3-C6; A30-B3-C7; A30-B3-C8; A30-B3-C9;
A30-B3-C10; A30-B3-C11; A30-B3-C12; A30-B3-C13; A30-B3-C14; A30-B3-C15;
A30-B3-C16; A30-B3-C17; A30-B3-C18; A30-B3-C19; A30-B3-C20; A30-B3-C21;
A30-B3-C22; A30-B3-C23; A30-B3-C24; A30-B3-C25; A30-B3-C26; A30-B3-C27;
A31-B3-C1; A31-B3-C2; A31-B3-C3; A31-B3-C4; A31-B3-C5; A31-B3-C6;
A31-B3-C7; A31-B3-C8; A31-B3-C9; A31-B3-C10; A31-B3-C11; A31-B3-C12;

A31-B3-C13; A31-B3-C14; A31-B3-C15; A31-B3-C16; A31-B3-C17; A31-B3-C18;
A31-B3-C19; A31-B3-C20; A31-B3-C21; A31-B3-C22; A31-B3-C23; A31-B3-C24;
A31-B3-C25; A31-B3-C26; A31-B3-C27; A32-B3-C1; A32-B3-C2; A32-B3-C3;
A32-B3-C4; A32-B3-C5; A32-B3-C6; A32-B3-C7; A32-B3-C8; A32-B3-C9;
A32-B3-C10; A32-B3-C11; A32-B3-C12; A32-B3-C13; A32-B3-C14; A32-B3-C15;
A32-B3-C16; A32-B3-C17; A32-B3-C18; A32-B3-C19; A32-B3-C20; A32-B3-C21;
A32-B3-C22; A32-B3-C23; A32-B3-C24; A32-B3-C25; A32-B3-C26; A32-B3-C27;
A33-B3-C1; A33-B3-C2; A33-B3-C3; A33-B3-C4; A33-B3-C5; A33-B3-C6;
A33-B3-C7; A33-B3-C8; A33-B3-C9; A33-B3-C10; A33-B3-C11; A33-B3-C12;
A33-B3-C13; A33-B3-C14; A33-B3-C15; A33-B3-C16; A33-B3-C17; A33-B3-C18;
A33-B3-C19; A33-B3-C20; A33-B3-C21; A33-B3-C22; A33-B3-C23; A33-B3-C24;
A33-B3-C25; A33-B3-C26; A33-B3-C27; A34-B3-C1; A34-B3-C2; A34-B3-C3;
A34-B3-C4; A34-B3-C5; A34-B3-C6; A34-B3-C7; A34-B3-C8; A34-B3-C9;
A34-B3-C10; A34-B3-C11; A34-B3-C12; A34-B3-C13; A34-B3-C14; A34-B3-C15;
A34-B3-C16; A34-B3-C17; A34-B3-C18; A34-B3-C19; A34-B3-C20; A34-B3-C21;
A34-B3-C22; A34-B3-C23; A34-B3-C24; A34-B3-C25; A34-B3-C26; A34-B3-C27;
A35-B3-C1; A35-B3-C2; A35-B3-C3; A35-B3-C4; A35-B3-C5; A35-B3-C6;
A35-B3-C7; A35-B3-C8; A35-B3-C9; A35-B3-C10; A35-B3-C11; A35-B3-C12;
A35-B3-C13; A35-B3-C14; A35-B3-C15; A35-B3-C16; A35-B3-C17; A35-B3-C18;
A35-B3-C19; A35-B3-C20; A35-B3-C21; A35-B3-C22; A35-B3-C23; A35-B3-C24;
A35-B3-C25; A35-B3-C26; A35-B3-C27; A36-B3-C1; A36-B3-C2; A36-B3-C3;
A36-B3-C4; A36-B3-C5; A36-B3-C6; A36-B3-C7; A36-B3-C8; A36-B3-C9;
A36-B3-C10; A36-B3-C11; A36-B3-C12; A36-B3-C13; A36-B3-C14; A36-B3-C15;
A36-B3-C16; A36-B3-C17; A36-B3-C18; A36-B3-C19; A36-B3-C20; A36-B3-C21;
A36-B3-C22; A36-B3-C23; A36-B3-C24; A36-B3-C25; A36-B3-C26; A36-B3-C27;
A1-B4-C1; A1-B4-C2; A1-B4-C3; A1-B4-C4; A1-B4-C5; A1-B4-C6;
A1-B4-C7; A1-B4-C8; A1-B4-C9; A1-B4-C10; A1-B4-C11; A1-B4-C12;
A1-B4-C13; A1-B4-C14; A1-B4-C15; A1-B4-C16; A1-B4-C17; A1-B4-C18;
A1-B4-C19; A1-B4-C20; A1-B4-C21; A1-B4-C22; A1-B4-C23; A1-B4-C24;
A1-B4-C25; A1-B4-C26; A1-B4-C27; A2-B4-C1; A2-B4-C2; A2-B4-C3;
A2-B4-C4; A2-B4-C5; A2-B4-C6; A2-B4-C7; A2-B4-C8; A2-B4-C9;
A2-B4-C10; A2-B4-C11; A2-B4-C12; A2-B4-C13; A2-B4-C14; A2-B4-C15;
A2-B4-C16; A2-B4-C17; A2-B4-C18; A2-B4-C19; A2-B4-C20; A2-B4-C21;
A2-B4-C22; A2-B4-C23; A2-B4-C24; A2-B4-C25; A2-B4-C26; A2-B4-C27;
A3-B4-C1; A3-B4-C2; A3-B4-C3; A3-B4-C4; A3-B4-C5; A3-B4-C6;

A3-B4-C7;	A3-B4-C8;	A3-B4-C9;	A3-B4-C10;	A3-B4-C11;	A3-B4-C12;
A3-B4-C13;	A3-B4-C14;	A3-B4-C15;	A3-B4-C16;	A3-B4-C17;	A3-B4-C18;
A3-B4-C19;	A3-B4-C20;	A3-B4-C21;	A3-B4-C22;	A3-B4-C23;	A3-B4-C24;
A3-B4-C25;	A3-B4-C26;	A3-B4-C27;	A4-B4-C1;	A4-B4-C2;	A4-B4-C3;
A4-B4-C4;	A4-B4-C5;	A4-B4-C6;	A4-B4-C7;	A4-B4-C8;	A4-B4-C9;
A4-B4-C10;	A4-B4-C11;	A4-B4-C12;	A4-B4-C13;	A4-B4-C14;	A4-B4-C15;
A4-B4-C16;	A4-B4-C17;	A4-B4-C18;	A4-B4-C19;	A4-B4-C20;	A4-B4-C21;
A4-B4-C22;	A4-B4-C23;	A4-B4-C24;	A4-B4-C25;	A4-B4-C26;	A4-B4-C27;
A5-B4-C1;	A5-B4-C2;	A5-B4-C3;	A5-B4-C4;	A5-B4-C5;	A5-B4-C6;
A5-B4-C7;	A5-B4-C8;	A5-B4-C9;	A5-B4-C10;	A5-B4-C11;	A5-B4-C12;
A5-B4-C13;	A5-B4-C14;	A5-B4-C15;	A5-B4-C16;	A5-B4-C17;	A5-B4-C18;
A5-B4-C19;	A5-B4-C20;	A5-B4-C21;	A5-B4-C22;	A5-B4-C23;	A5-B4-C24;
A5-B4-C25;	A5-B4-C26;	A5-B4-C27;	A6-B4-C1;	A6-B4-C2;	A6-B4-C3;
A6-B4-C4;	A6-B4-C5;	A6-B4-C6;	A6-B4-C7;	A6-B4-C8;	A6-B4-C9;
A6-B4-C10;	A6-B4-C11;	A6-B4-C12;	A6-B4-C13;	A6-B4-C14;	A6-B4-C15;
A6-B4-C16;	A6-B4-C17;	A6-B4-C18;	A6-B4-C19;	A6-B4-C20;	A6-B4-C21;
A6-B4-C22;	A6-B4-C23;	A6-B4-C24;	A6-B4-C25;	A6-B4-C26;	A6-B4-C27;
A7-B4-C1;	A7-B4-C2;	A7-B4-C3;	A7-B4-C4;	A7-B4-C5;	A7-B4-C6;
A7-B4-C7;	A7-B4-C8;	A7-B4-C9;	A7-B4-C10;	A7-B4-C11;	A7-B4-C12;
A7-B4-C13;	A7-B4-C14;	A7-B4-C15;	A7-B4-C16;	A7-B4-C17;	A7-B4-C18;
A7-B4-C19;	A7-B4-C20;	A7-B4-C21;	A7-B4-C22;	A7-B4-C23;	A7-B4-C24;
A7-B4-C25;	A7-B4-C26;	A7-B4-C27;	A8-B4-C1;	A8-B4-C2;	A8-B4-C3;
A8-B4-C4;	A8-B4-C5;	A8-B4-C6;	A8-B4-C7;	A8-B4-C8;	A8-B4-C9;
A8-B4-C10;	A8-B4-C11;	A8-B4-C12;	A8-B4-C13;	A8-B4-C14;	A8-B4-C15;
A8-B4-C16;	A8-B4-C17;	A8-B4-C18;	A8-B4-C19;	A8-B4-C20;	A8-B4-C21;
A8-B4-C22;	A8-B4-C23;	A8-B4-C24;	A8-B4-C25;	A8-B4-C26;	A8-B4-C27;
A9-B4-C1;	A9-B4-C2;	A9-B4-C3;	A9-B4-C4;	A9-B4-C5;	A9-B4-C6;
A9-B4-C7;	A9-B4-C8;	A9-B4-C9;	A9-B4-C10;	A9-B4-C11;	A9-B4-C12;
A9-B4-C13;	A9-B4-C14;	A9-B4-C15;	A9-B4-C16;	A9-B4-C17;	A9-B4-C18;
A9-B4-C19;	A9-B4-C20;	A9-B4-C21;	A9-B4-C22;	A9-B4-C23;	A9-B4-C24;
A9-B4-C25;	A9-B4-C26;	A9-B4-C27;	A10-B4-C1;	A10-B4-C2;	A10-B4-C3;
A10-B4-C4;	A10-B4-C5;	A10-B4-C6;	A10-B4-C7;	A10-B4-C8;	A10-B4-C9;
A10-B4-C10;	A10-B4-C11;	A10-B4-C12;	A10-B4-C13;	A10-B4-C14;	A10-B4-C15;
A10-B4-C16;	A10-B4-C17;	A10-B4-C18;	A10-B4-C19;	A10-B4-C20;	A10-B4-C21;
A10-B4-C22;	A10-B4-C23;	A10-B4-C24;	A10-B4-C25;	A10-B4-C26;	A10-B4-C27;


A11-B4-C1; A11-B4-C2 A11-B4-C3; A11-B4-C4; A11-B4-C5; A11-B4-C6;
A11-B4-C7; A11-B4-C8; A11-B4-C9; A11-B4-C10; A11-B4-C11; A11-B4-C12;
A11-B4-C13; A11-B4-C14; A11-B4-C15; A11-B4-C16; A11-B4-C17; A11-B4-C18;
A11-B4-C19; A11-B4-C20; A11-B4-C21; A11-B4-C22; A11-B4-C23; A11-B4-C24;
A11-B4-C25; A11-B4-C26; A11-B4-C27; A12-B4-C1; A12-B4-C2; A12-B4-C3;
A12-B4-C4; A12-B4-C5; A12-B4-C6; A12-B4-C7; A12-B4-C8; A12-B4-C9;
A12-B4-C10; A12-B4-C11; A12-B4-C12; A12-B4-C13; A12-B4-C14; A12-B4-C15;
A12-B4-C16; A12-B4-C17; A12-B4-C18; A12-B4-C19; A12-B4-C20; A12-B4-C21;
A12-B4-C22; A12-B4-C23; A12-B4-C24; A12-B4-C25; A12-B4-C26; A12-B4-C27;
A13-B4-C1; A13-B4-C2; A13-B4-C3; A13-B4-C4; A13-B4-C5; A13-B4-C6;
A13-B4-C7; A13-B4-C8; A13-B4-C9; A13-B4-C10; A13-B4-C11; A13-B4-C12;
A13-B4-C13; A13-B4-C14; A13-B4-C15; A13-B4-C16; A13-B4-C17; A13-B4-C18;
A13-B4-C19; A13-B4-C20; A13-B4-C21; A13-B4-C22; A13-B4-C23; A13-B4-C24;
A13-B4-C25; A13-B4-C26; A13-B4-C27; A14-B4-C1; A14-B4-C2; A14-B4-C3;
A14-B4-C4; A14-B4-C5; A14-B4-C6; A14-B4-C7; A14-B4-C8; A14-B4-C9;
A14-B4-C10; A14-B4-C11; A14-B4-C12; A14-B4-C13; A14-B4-C14; A14-B4-C15;
A14-B4-C16; A14-B4-C17; A14-B4-C18; A14-B4-C19; A14-B4-C20; A14-B4-C21;
A14-B4-C22; A14-B4-C23; A14-B4-C24; A14-B4-C25; A14-B4-C26; A14-B4-C27;
A15-B4-C1; A15-B4-C2; A15-B4-C3; A15-B4-C4; A15-B4-C5; A15-B4-C6;
A15-B4-C7; A15-B4-C8; A15-B4-C9; A15-B4-C10; A15-B4-C11; A15-B4-C12;
A15-B4-C13; A15-B4-C14; A15-B4-C15; A15-B4-C16; A15-B4-C17; A15-B4-C18;
A15-B4-C19; A15-B4-C20; A15-B4-C21; A15-B4-C22; A15-B4-C23; A15-B4-C24;
A15-B4-C25; A15-B4-C26; A15-B4-C27; A16-B4-C1; A16-B4-C2; A16-B4-C3;
A16-B4-C4; A16-B4-C5; A16-B4-C6; A16-B4-C7; A16-B4-C8; A16-B4-C9;
A16-B4-C10; A16-B4-C11; A16-B4-C12; A16-B4-C13; A16-B4-C14; A16-B4-C15;
A16-B4-C16; A16-B4-C17; A16-B4-C18; A16-B4-C19; A16-B4-C20; A16-B4-C21;
A16-B4-C22; A16-B4-C23; A16-B4-C24; A16-B4-C25; A16-B4-C26; A16-B4-C27;
A17-B4-C1; A17-B4-C2; A17-B4-C3; A17-B4-C4; A17-B4-C5; A17-B4-C6;
A17-B4-C7; A17-B4-C8; A17-B4-C9; A17-B4-C10; A17-B4-C11; A17-B4-C12;
A17-B4-C13; A17-B4-C14; A17-B4-C15; A17-B4-C16; A17-B4-C17; A17-B4-C18;
A17-B4-C19; A17-B4-C20; A17-B4-C21; A17-B4-C22; A17-B4-C23; A17-B4-C24;
A17-B4-C25; A17-B4-C26; A17-B4-C27; A18-B4-C1; A18-B4-C2; A18-B4-C3;
A18-B4-C4; A18-B4-C5; A18-B4-C6; A18-B4-C7; A18-B4-C8; A18-B4-C9;
A18-B4-C10; A18-B4-C11; A18-B4-C12; A18-B4-C13; A18-B4-C14; A18-B4-C15;
A18-B4-C16; A18-B4-C17; A18-B4-C18; A18-B4-C19; A18-B4-C20; A18-B4-C21;

A18-B4-C22; A18-B4-C23; A18-B4-C24; A18-B4-C25; A18-B4-C26; A18-B4-C27;
A19-B4-C1; A19-B4-C2; A19-B4-C3; A19-B4-C4; A19-B4-C5; A19-B4-C6;
A19-B4-C7; A19-B4-C8; A19-B4-C9; A19-B4-C10; A19-B4-C11; A19-B4-C12;
A19-B4-C13; A19-B4-C14; A19-B4-C15; A19-B4-C16; A19-B4-C17; A19-B4-C18;
A19-B4-C19; A19-B4-C20; A19-B4-C21; A19-B4-C22; A19-B4-C23; A19-B4-C24;
A19-B4-C25; A19-B4-C26; A19-B4-C27; A20-B4-C1; A20-B4-C2; A20-B4-C3;
A20-B4-C4; A20-B4-C5; A20-B4-C6; A20-B4-C7; A20-B4-C8; A20-B4-C9;
A20-B4-C10; A20-B4-C11; A20-B4-C12; A20-B4-C13; A20-B4-C14; A20-B4-C15;
A20-B4-C16; A20-B4-C17; A20-B4-C18; A20-B4-C19; A20-B4-C20; A20-B4-C21;
A20-B4-C22; A20-B4-C23; A20-B4-C24; A20-B4-C25; A20-B4-C26; A20-B4-C27;
A21-B4-C1; A21-B4-C2; A21-B4-C3; A21-B4-C4; A21-B4-C5; A21-B4-C6;
A21-B4-C7; A21-B4-C8; A21-B4-C9; A21-B4-C10; A21-B4-C11; A21-B4-C12;
A21-B4-C13; A21-B4-C14; A21-B4-C15; A21-B4-C16; A21-B4-C17; A21-B4-C18;
A21-B4-C19; A21-B4-C20; A21-B4-C21; A21-B4-C22; A21-B4-C23; A21-B4-C24;
A21-B4-C25; A21-B4-C26; A21-B4-C27; A22-B4-C1; A22-B4-C2; A22-B4-C3;
A22-B4-C4; A22-B4-C5; A22-B4-C6; A22-B4-C7; A22-B4-C8; A22-B4-C9;
A22-B4-C10; A22-B4-C11; A22-B4-C12; A22-B4-C13; A22-B4-C14; A22-B4-C15;
A22-B4-C16; A22-B4-C17; A22-B4-C18; A22-B4-C19; A22-B4-C20; A22-B4-C21;
A22-B4-C22; A22-B4-C23; A22-B4-C24; A22-B4-C25; A22-B4-C26; A22-B4-C27;
A23-B4-C1; A23-B4-C2; A23-B4-C3; A23-B4-C4; A23-B4-C5; A23-B4-C6;
A23-B4-C7; A23-B4-C8; A23-B4-C9; A23-B4-C10; A23-B4-C11; A23-B4-C12;
A23-B4-C13; A23-B4-C14; A23-B4-C15; A23-B4-C16; A23-B4-C17; A23-B4-C18;
A23-B4-C19; A23-B4-C20; A23-B4-C21; A23-B4-C22; A23-B4-C23; A23-B4-C24;
A23-B4-C25; A23-B4-C26; A23-B4-C27; A24-B4-C1; A24-B4-C2; A24-B4-C3;
A24-B4-C4; A24-B4-C5; A24-B4-C6; A24-B4-C7; A24-B4-C8; A24-B4-C9;
A24-B4-C10; A24-B4-C11; A24-B4-C12; A24-B4-C13; A24-B4-C14; A24-B4-C15;
A24-B4-C16; A24-B4-C17; A24-B4-C18; A24-B4-C19; A24-B4-C20; A24-B4-C21;
A24-B4-C22; A24-B4-C23; A24-B4-C24; A24-B4-C25; A24-B4-C26; A24-B4-C27;
A25-B4-C1; A25-B4-C2; A25-B4-C3; A25-B4-C4; A25-B4-C5; A25-B4-C6;
A25-B4-C7; A25-B4-C8; A25-B4-C9; A25-B4-C10; A25-B4-C11; A25-B4-C12;
A25-B4-C13; A25-B4-C14; A25-B4-C15; A25-B4-C16; A25-B4-C17; A25-B4-C18;
A25-B4-C19; A25-B4-C20; A25-B4-C21; A25-B4-C22; A25-B4-C23; A25-B4-C24;
A25-B4-C25; A25-B4-C26; A25-B4-C27; A26-B4-C1; A26-B4-C2; A26-B4-C3;
A26-B4-C4; A26-B4-C5; A26-B4-C6; A26-B4-C7; A26-B4-C8; A26-B4-C9;
A26-B4-C10; A26-B4-C11; A26-B4-C12; A26-B4-C13; A26-B4-C14; A26-B4-C15;

A26-B4-C16; A26-B4-C17; A26-B4-C18; A26-B4-C19; A26-B4-C20; A26-B4-C21;
A26-B4-C22; A26-B4-C23; A26-B4-C24; A26-B4-C25; A26-B4-C26; A26-B4-C27;
A27-B4-C1; A27-B4-C2; A27-B4-C3; A27-B4-C4; A27-B4-C5; A27-B4-C6;
A27-B4-C7; A27-B4-C8; A27-B4-C9; A27-B4-C10; A27-B4-C11; A27-B4-C12;
A27-B4-C13; A27-B4-C14; A27-B4-C15; A27-B4-C16; A27-B4-C17; A27-B4-C18;
A27-B4-C19; A27-B4-C20; A27-B4-C21; A27-B4-C22; A27-B4-C23; A27-B4-C24;
A27-B4-C25; A27-B4-C26; A27-B4-C27; A28-B4-C1; A28-B4-C2; A28-B4-C3;
A28-B4-C4; A28-B4-C5; A28-B4-C6; A28-B4-C7; A28-B4-C8; A28-B4-C9;
A28-B4-C10; A28-B4-C11; A28-B4-C12; A28-B4-C13; A28-B4-C14; A28-B4-C15;
A28-B4-C16; A28-B4-C17; A28-B4-C18; A28-B4-C19; A28-B4-C20; A28-B4-C21;
A28-B4-C22; A28-B4-C23; A28-B4-C24; A28-B4-C25; A28-B4-C26; A28-B4-C27;
A29-B4-C1; A29-B4-C2; A29-B4-C3; A29-B4-C4; A29-B4-C5; A29-B4-C6;
A29-B4-C7; A29-B4-C8; A29-B4-C9; A29-B4-C10; A29-B4-C11; A29-B4-C12;
A29-B4-C13; A29-B4-C14; A29-B4-C15; A29-B4-C16; A29-B4-C17; A29-B4-C18;
A29-B4-C19; A29-B4-C20; A29-B4-C21; A29-B4-C22; A29-B4-C23; A29-B4-C24;
A29-B4-C25; A29-B4-C26; A29-B4-C27; A30-B4-C1; A30-B4-C2; A30-B4-C3;
A30-B4-C4; A30-B4-C5; A30-B4-C6; A30-B4-C7; A30-B4-C8; A30-B4-C9;
A30-B4-C10; A30-B4-C11; A30-B4-C12; A30-B4-C13; A30-B4-C14; A30-B4-C15;
A30-B4-C16; A30-B4-C17; A30-B4-C18; A30-B4-C19; A30-B4-C20; A30-B4-C21;
A30-B4-C22; A30-B4-C23; A30-B4-C24; A30-B4-C25; A30-B4-C26; A30-B4-C27;
A31-B4-C1; A31-B4-C2; A31-B4-C3; A31-B4-C4; A31-B4-C5; A31-B4-C6;
A31-B4-C7; A31-B4-C8; A31-B4-C9; A31-B4-C10; A31-B4-C11; A31-B4-C12;
A31-B4-C13; A31-B4-C14; A31-B4-C15; A31-B4-C16; A31-B4-C17; A31-B4-C18;
A31-B4-C19; A31-B4-C20; A31-B4-C21; A31-B4-C22; A31-B4-C23; A31-B4-C24;
A31-B4-C25; A31-B4-C26; A31-B4-C27; A32-B4-C1; A32-B4-C2; A32-B4-C3;
A32-B4-C4; A32-B4-C5; A32-B4-C6; A32-B4-C7; A32-B4-C8; A32-B4-C9;
A32-B4-C10; A32-B4-C11; A32-B4-C12; A32-B4-C13; A32-B4-C14; A32-B4-C15;
A32-B4-C16; A32-B4-C17; A32-B4-C18; A32-B4-C19; A32-B4-C20; A32-B4-C21;
A32-B4-C22; A32-B4-C23; A32-B4-C24; A32-B4-C25; A32-B4-C26; A32-B4-C27;
A33-B4-C1; A33-B4-C2; A33-B4-C3; A33-B4-C4; A33-B4-C5; A33-B4-C6;
A33-B4-C7; A33-B4-C8; A33-B4-C9; A33-B4-C10; A33-B4-C11; A33-B4-C12;
A33-B4-C13; A33-B4-C14; A33-B4-C15; A33-B4-C16; A33-B4-C17; A33-B4-C18;
A33-B4-C19; A33-B4-C20; A33-B4-C21; A33-B4-C22; A33-B4-C23; A33-B4-C24;
A33-B4-C25; A33-B4-C26; A33-B4-C27; A34-B4-C1; A34-B4-C2; A34-B4-C3;
A34-B4-C4; A34-B4-C5; A34-B4-C6; A34-B4-C7; A34-B4-C8; A34-B4-C9

A34-B4-C10; A34-B4-C11; A34-B4-C12; A34-B4-C13; A34-B4-C14; A34-B4-C15;
 A34-B4-C16; A34-B4-C17; A34-B4-C18; A34-B4-C19; A34-B4-C20; A34-B4-C21;
 A34-B4-C22; A34-B4-C23; A34-B4-C24; A34-B4-C25; A34-B4-C26; A34-B4-C27;
 A35-B4-C1; A35-B4-C2; A35-B4-C3; A35-B4-C4; A35-B4-C5; A35-B4-C6;
 A35-B4-C7; A35-B4-C8; A35-B4-C9; A35-B4-C10; A35-B4-C11; A35-B4-C12;
 A35-B4-C13; A35-B4-C14; A35-B4-C15; A35-B4-C16; A35-B4-C17; A35-B4-C18;
 A35-B4-C19; A35-B4-C20; A35-B4-C21; A35-B4-C22; A35-B4-C23; A35-B4-C24;
 A35-B4-C25; A35-B4-C26; A35-B4-C27; A36-B4-C1; A36-B4-C2; A36-B4-C3;
 A36-B4-C4; A36-B4-C5; A36-B4-C6; A36-B4-C7; A36-B4-C8; A36-B4-C9;
 A36-B4-C10; A36-B4-C11; A36-B4-C12; A36-B4-C13; A36-B4-C14; A36-B4-C15;
 A36-B4-C16; A36-B4-C17; A36-B4-C18; A36-B4-C19; A36-B4-C20; A36-B4-C21;
 A36-B4-C22; A36-B4-C23; A36-B4-C24; A36-B4-C25; A36-B4-C26; A36-B4-C27.

Thus, for example, in the above list the compound denoted as A1-B1-C1 is the product of the combination of group A1 in Table 1 and B1 in Table 2 and C1 in Table 3, namely



5 Preferred compounds of the invention are:-

(R) 3-{4-[2-(4-methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetylamino]phenyl}butanoic acid;
 (R) 3-{4-[2-(4-methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylamino]phenyl}-butanoic acid;
 (R,S) 3-phenyl-3-[4-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl]-propanoic acid;
 and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and
 10 solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further
 15 aspect, compounds of the invention and compositions containing compounds of the invention for use in therapy.

Compounds within the scope of the present invention block the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$) according to tests described in the literature and

described in vitro and in vivo procedures hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or
5 subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4 \beta 1$ mediated cell adhesion. For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis.

10 Additionally, the compounds are useful in the treatment of acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, colitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, multiple sclerosis, asthma, psoriasis restenosis, myocarditis, inflammatory bowel disease and melanoma cell division in metastasis.

15 A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

20 Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

According to a further feature of the invention there is provided a method for the treatment of a
25 human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4 \beta 1$), for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe
30 an amount of compound of the present invention effective in inhibiting the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4 \beta 1$), and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as
35 treatment of established conditions.

The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.

5

Compounds of the invention may be administered by any suitable means. In practice compounds of the present invention may generally be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.

- 10 Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more
- 15 agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose,
- 20 sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate, sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension.
- 25 Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or

- 30 aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also comprising solutions of the salts in pure distilled water, may be used for intravenous
- 35 administration with the proviso that their pH is suitably adjusted, that they are judiciously

buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

For administration by inhalation compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained. Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in Comprehensive Organic Transformations, VCH publishers, 1989.

In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.


Compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined, and Y is carboxy may be prepared by hydrolysis of esters of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and where the Y is a $-CO_2R^{10}$ group (in which R^{10} is alkyl, alkenyl or arylalkyl). The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50°C to about 80°C.

As another example compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined, and Y is carboxy may be prepared by acid catalysed removal of the tert-butyl group of tert-butyl esters of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and Y is a $-CO_2R^{10}$ group (in which R^{10} is tert-butyl), using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.


As another example compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and Y is carboxy may be prepared by hydrogenation of compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and Y is a $-CO_2R^{10}$

group (in which R^{10} is benzyl). The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined L^1 is a $-R^3-R^4$ - linkage (in which R^3 is as hereinbefore defined and R^4 is $-C(=O)-NR^5$ -) and Y is a $-CO_2R^{10}$ group (in which R^{10} is as hereinbefore defined) may be prepared by reaction of compounds of formula (II):-



wherein Het, R^1 , R^3 and Z^1 are as hereinbefore and X^1 is a hydroxy group or a halogen, preferably chlorine, atom, with amines of formula (III):-




wherein R^2 , R^5 , R^{10} and L^2 are as hereinbefore defined. When X^1 is a hydroxy group the reaction may be carried out using standard peptide coupling procedures for example coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide), at room temperature. When X^1 is a halogen atom the acylation reaction may be carried out with the aid of a base, such pyridine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature.

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined L^1 is a $-R^3-R^4$ - linkage [in which R^3 is as hereinbefore defined, and R^4 is $-NR^5-C(=O)-$ (where R^5 is as hereinbefore defined)] and Y is a $-CO_2R^{10}$ group (in which R^{10} is as hereinbefore defined) may be prepared by reaction of compounds of formula (IV):-



wherein Het, R^1 , R^3 , R^5 and Z^1 are as hereinbefore, with compounds of formula (V):-




wherein R^2 , R^{10} and L^2 are as hereinbefore defined and X^2 is a hydroxy group or a halogen, preferably chlorine, atom, using procedures described hereinbefore for coupling acids or acid halides with amines.

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4-$ linkage (in which R^3 is as hereinbefore defined and R^4 is $-O-$) and Y is a $-\text{CO}_2 R^{10}$ group (in which R^{10} is as hereinbefore defined) may be prepared by reaction of compounds of formula (VI):-



wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined with compounds of formula (VII):-




wherein R^2 , R^{10} and L^2 are as hereinbefore defined and Z^2 is O, in the presence of a dialkyl azodicarboxylate, such as diethyl azodicarboxylate, and triphenylphosphine, preferably in a dry ethereal solvent, e.g. diethyl ether or tetrahydrofuran, preferably at or near room temperature.

Alternatively esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4-$ linkage (in which R^3 is as hereinbefore defined and R^4 is $-O-$) and Y is a

-CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be prepared by alkylation of compounds of formula (VII), wherein R², R¹⁰ and L² are as hereinbefore defined and Z² is O with the appropriate alkyl bromides of formula (VIII):-

5




Het, R¹, R³ and Z¹ are as hereinbefore defined and X³ is a halogen, preferably bromo, atom using standard alkylation conditions. The alkylation may for example be carried out in the presence of a base, such as an alkali metal carbonate, e.g. potassium carbonate, or alkali metal
10 hydride, e.g. sodium hydride, in dimethylformamide, or dimethyl sulphoxide, at a temperature from about 0°C to about 100°C.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage (in which R³ is as hereinbefore defined and R⁴ is -S-) and Y is a -CO₂R¹⁰
15 group (in which R¹⁰ is as hereinbefore defined) may be similarly prepared by alkylation of compounds of formula (VII) wherein R², R¹⁰ and L² are as hereinbefore defined and Z² is S.


Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -NR⁵- (where R⁵ is as
20 hereinbefore defined)] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be similarly prepared by alkylation of compounds of formula (III), wherein R², R⁵, R¹⁰ and L² are as hereinbefore defined.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a
25 -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -C(=O)-] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be prepared by reaction of esters of formula (IX):-



30

wherein Het, R¹, R³ and Z¹ are as hereinbefore defined and R¹⁰ is lower alkyl, with Grignard reagents derived from reaction of compounds of formula (X):-




5

wherein R² and L² are as hereinbefore defined and X⁴ is a suitably protected carboxylic acid group, with magnesium using standard reaction conditions, followed by removal of the carboxylic acid protecting group.

- 10 Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -NR⁵-C(=O)-NH- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be prepared by reaction of compounds of formula (IV) wherein Het, R¹, R³, R⁵ and Z¹ are as hereinbefore defined, with isocyanates of formula (XI):-

15




wherein R², R¹⁰ and L² are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as dichloromethane, and at a temperature at about room temperature.

20


Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -NH-C(=O)-NR⁵- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be similarly prepared by reaction of amines of formula (III) wherein R², R⁵, R¹⁰ and L² are as hereinbefore defined with compounds of formula (XII):-

25



wherein Het, R¹, R³ and Z¹ are as hereinbefore defined.

5 Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -SO₂-NR⁵- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be prepared by reaction of compounds of formula (XIII):-




10

wherein Het, R¹, R³ and Z¹ are as hereinbefore defined, with amines of formula (III) wherein R², R⁵, R¹⁰ and L² are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature.

15

Esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -NR⁵-SO₂- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹⁰ group (in which R¹⁰ is as hereinbefore defined) may be similarly prepared by reaction of compounds of formula (IV) wherein Het, R¹, R³, R⁵ and Z¹ are as hereinbefore defined with sulphonyl chlorides of formula (XIV):-

20



wherein R², R¹⁰ and L² are as hereinbefore defined.

25

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R³-R⁴- linkage [in which R³ is as hereinbefore defined and R⁴ is -O-C(=O)-] and Y is a -CO₂R¹⁰ group (where R¹⁰ is as hereinbefore defined) may be prepared by O-acylation of compounds of formula (VI) wherein Het, R¹, R³, and Z¹ are as hereinbefore defined with

compounds of formula (V) wherein R^2 , R^{10} and L^2 are as hereinbefore defined and X^2 is a chlorine atom. The reaction may be carried using standard O-acylation conditions, for example reaction in the presence of a base, such as triethylamine or pyridine, at a temperature from about 0°C to about room temperature.

5

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4$ - linkage [in which R^3 is as hereinbefore defined and R^4 is $-C(=O)-O-$] and Y is a $-\text{CO}_2R^{10}$ group (where R^{10} is as hereinbefore defined) may be similarly prepared by O-acylation of compounds of formula (VII) wherein R^2 , R^{10} and L^2 are as hereinbefore defined and Z^2 is O with compounds of formula (II) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and X^1 is a chlorine atom.

10

Esters of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4$ - linkage (in which R^3 is as hereinbefore defined and R^4 is $-O-C(=O)-\text{NH}-$) and Y is a $-\text{CO}_2R^{10}$ group (where R^{10} is as hereinbefore defined) may be prepared by reaction of compounds of formula (VI) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined with isocyanates of formula (XI) wherein R^2 , R^{10} and L^2 are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as dichloromethane, and at a temperature at about room temperature.

15


20

Esters of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4$ - linkage (in which R^3 is as hereinbefore defined and R^4 is $-\text{NH}-C(=O)-O-$) and Y is a $-\text{CO}_2R^{10}$ group (where R^{10} is as hereinbefore defined) may be similarly prepared by reaction of isocyanates of formula (XII) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined with compounds of formula (VII) wherein R^2 , R^{10} and L^2 are as hereinbefore defined and Z^2 is O.


25

30

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^3-R^4$ - linkage (in which R^3 is a direct bond and R^4 is a straight or branched chain C_{2-6} alkenylene chain where the carbon-carbon double bond is directly attached to the phenyl ring containing the $-L^2-Y$ group) may be prepared by reaction of compounds of formula (XV):-





wherein R^2 , R^{10} and L^2 are as hereinbefore defined, with an appropriate phosphorane (or phosphonate ester) of formula (XVI):-



wherein Het, R^1 and Z^1 are as hereinbefore defined, R^3 is a straight or branched chain C_{1-5} alkylene chain and X^5 is $=\text{PPh}_3^+\text{Br}^-$ (or $-\text{P}(=\text{O})(\text{OEt})_2$), using standard Wittig (or Horner-Wadsworth-Emmons) coupling procedures (for example those described in Tetrahedron Organic Chemistry Series Volume 11, Organic Synthesis Based On Name Reactions and Unnamed reactions, Editors, J. E. Balwin and P. D. Magnus, pages 181 and 421).


Lactones of formula (I) wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined and the




borane derivative or lithium borohydride) of compounds of formula (I) wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined and the moiety $-\text{L}^2-\text{Y}$ is  in which R^{11} is

lower alkyl, followed by spontaneous cyclisation of the intermediate hydroxy compound. The reduction can be achieved by the application or adaptation of the procedures described by C.J.Francis and J. Bryan Jones, J. Chem. Soc, Chem. Commun., 1984, (9), 579-58, J.Hiratake et al, J. Chem. Soc, Perkin Trans, 1987, 1 (5), 1053-8 or L.K.P.Lam et al, J. Org. Chem. (1986), 51(11), 2047-50.

Lactones of formula (I) wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined and the


moiety -L²-Y is  may be similarly prepared from compounds of formula (I)

wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined and the moiety -L²-Y is




5

Lactones of formula (I) wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined and the


moiety -L²-Y is  may be similarly prepared from compounds of formula (I)

wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined and the moiety -L²-Y is





10

Compounds of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, and Y is carboxy, represented by formula (XVII), may be prepared using resin technology as shown in scheme 1.



SCHEME 1

For example Wang resin, 4-hydroxymethylphenoxyated styrene/divinylbenzene copolymer,


where  represents the polymeric core (comprising polystyrene crosslinked with 1% to 2% divinylbenzene), may be treated, in Step 1, with acids of formula (XVIII):-




wherein R^2 and L^2 are as hereinbefore defined, with diisopropyl carbodiimide in dimethylformamide, in the presence of dimethylaminopyridine, at room temperature. The


10 resulting esters (Resin 1), wherein R^2 , L^2 and  are as hereinbefore defined, may then be treated, in Step 2, with tin chloride in dimethylformamide at room temperature to give Resin 2, wherein R^2 , L^2 and  are as hereinbefore defined. Resin 2 may then be coupled, in


Step 3, with acids of general formula (II) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore and X^1 is hydroxy, in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
15 hexafluorophosphate and diisopropylethylamine in dimethylformamide, at room temperature.

The resulting Resin 3, wherein Het, R^1 , R^2 , R^3 , L^2 , Z^1 and R^2 , L^2 and  are as hereinbefore defined, may then be treated, in Step 4, with trifluoroacetic acid in an inert solvent such as dichloromethane, at room temperature, to liberate the acids of general formula (XVII), wherein Het, R^1 , R^2 , R^3 , L^2 and Z^1 are as hereinbefore defined.

20 Compounds of formula (Ia) wherein R^1 , R^2 , R^3 , R^{13} and L^2 are as hereinbefore defined, R^5 is hydrogen, X is O, Z^1 is NH and Y is carboxy, represented by formula (XVIIa), may be prepared using resin technology as shown in scheme 2.

SCHEME 2

For example Resin 2 may be coupled, in Step 1, with acids of general formula (XXI) wherein R^3 and R^{13} are as hereinbefore and X is O, in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and diisopropylethylamine in dimethylformamide, at room temperature to give Resin 4 wherein R^2 , R^3 , L^2 and  are as hereinbefore

defined. Resin 4 may then be treated with tin chloride in dimethylformamide at room temperature followed treatment with isocyanates of formula $R^1-N=C=O$ in dimethylformamide at room temperature and then treatment with diisopropylcarbodiimide in dimethylformamide at 75°C. The resulting Resin 5, wherein R^1 , R^2 , R^3 , L^2 and  are as hereinbefore defined,

5 may then be treated, in Step 3, with trifluoroacetic acid in an inert solvent such as dichloromethane, at room temperature, to liberate the acids of general formula (XVIIa), wherein R^1 , R^2 , R^3 and L^2 are as hereinbefore defined.

10 According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.

For example compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and Y is $-C(=O)-NHOH$, may be prepared by reaction of compounds of formula (I) wherein Het, R^1 , R^2 , L^1 , L^2 and Z^1 are as hereinbefore defined and Y is carboxy, with 15 hydroxylamine using standard peptide coupling procedures such as treatment with a carbodiimide, for example dicyclohexylcarbodiimide, in the presence of triethylamine, in an inert solvent such as dichloromethane or tetrahydrofuran and at a temperature at about room temperature. The coupling may also be carried out using 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in dichloromethane at room temperature. The 20 preparation may also be carried out using an O-protected hydroxylamine such as O-(trimethylsilyl)hydroxylamine, O-(t-butyl dimethylsilyl)-hydroxylamine, or O-(tetrahydropyranyl)hydroxylamine followed by treatment with acid.

As another example of the interconversion process, compounds of formula (I) wherein Het, R^1 , 25 R^2 , L^1 , Z^1 and Y are as hereinbefore defined and L^2 is an optionally substituted alkylene linkage, may be prepared by hydrogenation of the corresponding compounds of formula (I) in which L^2 is the corresponding optionally substituted alkenylene linkage. The hydrogenation may be carried out using hydrogen (optionally under pressure) in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as 30 carbon, preferably in a solvent such as methanol or ethanol, and at a temperature at about room temperature.

As another example of the interconversion process, compounds of formula (I) wherein Het, R¹, R², L², Z¹ and Y are as hereinbefore described and L¹ is a -R³-R⁴- linkage where R³ is a straight or branched chain C₂₋₆alkylene chain and R⁴ is a direct bond, may be similarly prepared by hydrogenation of the corresponding compounds of formula (I) in which L¹ is a -R³-R⁴- linkage where R³ is a straight or branched chain C₂₋₆alkenylene chain and R⁴ is a direct bond.

As another example of the interconversion process, compounds of the invention containing a heterocyclic group wherein the hetero atom is a nitrogen atom may be oxidised to their corresponding N-oxides. The oxidation may conveniently be carried out by means of reaction with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature, for example at a temperature of about 60-90°C. Alternatively, the oxidation may be carried out by reaction with a peracid, for example peracetic acid or m-chloroperoxybenzoic acid, in an inert solvent such as chloroform or dichloromethane, at a temperature from about room temperature to reflux, preferably at elevated temperature. The oxidation may alternatively be carried out by reaction with hydrogen peroxide in the presence of sodium tungstate at temperatures between room temperature and about 60°C.

It will be appreciated that compounds of the present invention may contain asymmetric centres. These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating

the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

5 The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.


10 Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.

15 Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.


20 According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

25

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Acids of formula (II) wherein Het is  (in which R¹³ is as hereinbefore defined),


30 R¹ and R³ are as hereinbefore defined, Z¹ is NH and X¹ is hydroxy may be prepared by reaction of compounds of formula (XIX):-



(XIX)

wherein R^3 and R^{13} are as hereinbefore defined, R^{10} is lower alkyl and X is O, with isocyanates of formula $R^1-N=C=O$ in ethanol and at room temperature, followed by reaction with a carbodiimide, such as dicyclohexylcarbodiimide or diisopropylcarbodiimide in ethanol and at a temperature from about room temperature to about reflux temperature, and subsequent hydrolysis using standard conditions, for example those described hereinbefore.


Compounds of general formula (XIX) wherein R^{13} is as hereinbefore defined, R^3 is an alkylene chain, X is O, and R^{10} is lower alkyl may be prepared by the reduction of compounds of general formula (XX):-



(XX)

wherein R^{13} and R^3 are as hereinbefore defined, X is O, and R^{10} is lower alkyl. The reduction may be carried out using standard methods, such as those described hereinbefore, for example hydrogenation in the presence of palladium. This method is particularly suitable for the preparation of compounds of formula (XIX) where R^3 is methylene and R^{13} is lower alkoxy.


Compounds of general formula (XX) wherein R^3 and R^{13} are as hereinbefore defined, X is O and R^{10} is lower alkyl may be prepared by esterification of compounds of formula (XXI):-



(XXI)


wherein R^3 and R^{13} are as hereinbefore defined and X is O using standard methods as described hereinbefore, for example reaction with a lower alkyl alcohol (e.g. methanol) in the presence of a mineral acid, e.g. concentrated sulphuric acid.

- 5 Compounds of formula (XX) wherein R^3 , R^{10} and R^{13} are as hereinbefore defined and X is O may also be prepared by reaction of compounds of formula (XXII):-



- 10 wherein R^3 , R^{10} and R^{13} are as hereinbefore defined and R^{14} is a suitable protecting group, such as alkyl- or arylcarbonyl, with a base, such as lithium hydroxide at a temperature at about room temperature. This method is particularly suitable for the preparation of compounds of formula (XX) where R^3 is methylene, R^{13} is lower alkyl and R^{10} is tertiary butyl.


- 15 Compounds of general formula (XXI) wherein R^3 and R^{13} are as hereinbefore defined and X is O may be prepared by reaction of compounds of general formula (XXIII):-



- 20 wherein R^3 and R^{13} are as hereinbefore defined by reaction with pyridine hydrochloride at a temperature at about room temperature.

Compounds of formula (XXII) wherein R^3 , R^{10} are as hereinbefore defined, R^{13} is a lower alkyl group attached to the ring position adjacent to the nitro group and R^{14} is a suitable protecting group, such as alkyl- or arylcarbonyl, may be prepared by reaction of compounds of formula (XXIV):-


25



(XXIV)


wherein R^3 , R^{10} are as hereinbefore defined and R^{14} is a suitable protecting group, such as alkyl- or arylcarbonyl, with a lower alkyl magnesium halide, such as methyl magnesium chloride, in an inert solvent, such as tetrahydrofuran, and at a temperature at about -15°C .

Compounds of general formula (XXIII) wherein R^3 is as hereinbefore defined and R^{13} is a methoxy group which is attached at the ring position adjacent to the nitro group, may be prepared by the treatment of compounds of general formula (XXV):-



(XXV)

wherein R^3 and R^{10} are as hereinbefore defined with sodium methoxide, followed by hydrolysis of the ester using standard conditions for example those described hereinbefore.

Acids of formula (II) wherein Het is , R^1 , R^3 and R^{13} are as hereinbefore

defined, Z^1 is NH and X^1 is hydroxy may be similarly prepared from compounds of formula (XIX) wherein R^3 , R^{10} and R^{13} are as hereinbefore defined and X is NH.

Acid chlorides of formula (II) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and X^1 is a chlorine atom may be prepared from the corresponding acids of formula (II) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and X^1 is hydroxy, by the application of standard procedures for the conversion of acids to acid chlorides for example by reaction with oxalyl chloride.

Compounds of formula (III) wherein R^2 , R^{10} and L^2 are as hereinbefore defined and R^5 is hydrogen may be prepared by reduction of the corresponding nitro compounds. The reduction may be carried out using iron powder and ammonium chloride, in aqueous ethanol at a temperature at about reflux. The reduction may also be carried out by hydrogenation using standard conditions, for example those described hereinbefore.

Compounds of formula (XIX) wherein R^3 , R^{10} and R^{13} are as hereinbefore defined and X is NH may be similarly prepared by reduction of the corresponding nitro-amino compounds or dinitro compounds.

10

Compounds of formula (IV) wherein Het , R^1 , R^3 and Z^1 are as hereinbefore defined and R^5 is hydrogen may be prepared by reaction of compounds of formula (VIII) wherein Het , R^1 , R^3 and Z^1 are as hereinbefore defined and X^3 is bromo with phthalimide potassium salt in dimethylformamide followed by reaction with hydrazine hydrate in ethanol (for example using the conditions described by O. Diouf et al., Heterocycles, 1995, 41, page 1219-1233).


15

Compounds of formula (IV) wherein Het , R^1 , R^3 and Z^1 are as hereinbefore defined and R^5 is methyl may be prepared by treatment of the corresponding compounds of formula (IV) wherein Het , R^1 , R^3 and Z^1 are as hereinbefore defined and R^5 is hydrogen with formic acetic anhydride followed by reduction with lithium aluminium hydride according to the procedure described by L. G. Humber et al, J. Med. Chem., 1971, 14, page 982.

20

Compounds of formula (VI) wherein Het , R^1 and Z^1 are as hereinbefore defined and R^3 is methylene, may be prepared by reduction of esters of formula (XXVI):-

25



30

wherein Het , R^1 and Z^1 are as hereinbefore defined, R^{10} is alkyl and R^{12} is a direct bond. The reduction may conveniently be carried out with diisobutylaluminium hydride in an inert solvent, such as tetrahydrofuran, at a temperature from about $-78^\circ C$ to about room temperature. The reduction may also be carried out with lithium aluminium hydride in an inert solvent, such as an ether, for example diethyl ether, at a temperature from about room temperature to about reflux.

Compounds of formula (VI) in which R^3 is a straight chain alkylene other than methylene may be similarly prepared esters of formula (XX) in which R^{12} is the appropriate alkylene chain containing one carbon atom less than the alkylene chain in R^3 as just defined.

5 Compounds of formula (VIII) wherein Het, R^1 and Z^1 are as hereinbefore defined, R^3 is an alkylene chain and X^3 is bromo may be prepared by reaction of compounds of formula (VI) wherein Het, R^1 and Z^1 are as hereinbefore defined, R^3 is an alkylene chain with phosphorus tribromide in an inert solvent such as carbon tetrachloride and at a temperature at about room temperature.

10

Esters of formula (IX) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and R^{10} is lower alkyl may be prepared from the corresponding acids of formula (II) by standard esterification procedures for example reaction with a lower alkyl alcohol (e.g. methanol) in the presence of an acid catalyst, such as hydrogen chloride or sulphuric acid.

15

Esters of formula (XXVI) wherein Het, R^1 , R^{12} and Z^1 are as hereinbefore defined and R^{10} is alkyl may be similarly prepared from the corresponding acids.

20 Compounds of formula (X) wherein R^2 , R^{10} and L^2 are as hereinbefore defined may be prepared from bromo-iodobenzene by the adaptation of procedures described by Y. Tamaru et al, Tetrahedron Letters, 1985, 26, page 5559 and 1986, 27, page 955.

25 Compounds of formula (XII) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined may be prepared from compounds of formula (IV) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and R^5 is hydrogen with phosgene following standard reaction conditions for the conversion of amines to isocyanates.

30 Compounds of formula (XIII) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined may be prepared by reaction of compounds of formula (VIII) wherein Het, R^1 , R^3 and Z^1 are as hereinbefore defined and X^3 is a bromine atom with sodium sulphite then with phosphorus trichloride according to the procedure described by P.N. Culshaw and J.C. Walton, J. Chem. Soc., Perkin Trans II, 1991, 8, page 1201-1208.

Compounds of formula (XVI) wherein Het, R¹ and Z¹ are as hereinbefore defined, R³ is a straight or branched chain C₁₋₅alkylene chain and X⁵ is =PPh₃⁺Br⁻ may be prepared by reaction of compounds of formula (VIII) wherein Het, R¹, R³ and Z¹ are as hereinbefore defined and X³ is a bromine atom by reaction with triphenylphosphine in an inert solvent and at a temperature from about room temperature to about reflux temperature of the solvent.

The present invention is further Exemplified but not limited by the following illustrative Examples and Reference Examples.

- 10 High Pressure Liquid Chromatography/ Mass Spectrometry (LC-MS) conditions for determination of retention times (R_T) were as follows: 3 micron Luna C18 (2) HPLC column (30mm x 4.6mm) operated under gradient elution conditions with mixtures of (A) water containing 0.1 % formic acid and (B) acetonitrile containing 0.1 % formic acid as the mobile phase gradient : 0.00 minutes, 95 %A:5 %B; 0.50 minutes, 95 %A:5 %B; 4.50 minutes, 5 %A:95 %B; 5.00 minutes, 5 %A:95 %B; 5.50 minutes, 95 %A:5 %B; flow rate 2ml/minute with approximately 200µl/minute split to the Mass Spectrometer; injection volume 10-40µl; in line Diode Array (220-450nm), in line Evaporative light scattering (ELS) detection ELS - temperature 50°C, Gain 8 - 1.8ml/minute; Source temperature 150°C.
- 20 Accurate Mass spectra were recorded on a Bruker 3T Ion cyclotron mass spectrometer.

EXAMPLE 1

3(R)-{4-[2-(2-o-tolylaminobenzoxazol-6-yl)acetylaminophenyl]}butanoic acid

- A solution of 2-(o-tolylaminobenzoxazol-6-yl)acetic acid (1.0g, Reference Example 4) in dimethylformamide (75mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (1.35g), then with diisopropylethylamine (1.2mL) and then with ethyl (R)-3-(4-aminophenyl)butanoate (0.74g, Reference Example 1). The mixture was kept at room temperature for an hour and then evaporated to low bulk. The residue was partitioned between hydrochloric acid (1M) and dichloromethane. The organic phase was washed with aqueous bicarbonate solution (5 %) then with water, then dried, and then evaporated. The residue was suspended in ethanol (about 50mL). The mixture was treated with aqueous sodium hydroxide (about 5mL, 1M), then refluxed for 2 hours, then evaporated. The residue was triturated with aqueous hydrochloric acid (1M) then filtered. The insoluble material was washed with water, and then dried to give the title compound (0.48g) as a white powder.

MS: accurate mass = 444.1936 (calculated 444.1923 MH⁺). LC-MS: R_T = 3.19 minutes (100% by ELSD); MS (ES⁺), 444 (MH⁺).

EXAMPLE 2

5 (R)-3-{4-[2-(2-*o*-tolylamino-3H-benzimidazol-5-yl)acetylaminophenyl]}butanoic acid dihydrate
A solution of 2-(2-*o*-tolylamino)benzimidazole-5-acetic acid hydrochloride (200mg, Reference Example 7), ethyl (R)-3-(4-aminophenyl)butanoate (147mg, Reference Example 1) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (300mg) in dimethylformamide (5mL) was treated with diisopropylethylamine (470mg). After stirring at
10 room temperature for 2 hours the reaction mixture was partitioned between ethyl acetate and dilute aqueous acetic acid. The layers were separated and the organic layer was washed with 5% aqueous sodium bicarbonate solution, then dried, and then evaporated. The yellow semi-solid residue (120mg) was dissolved in ethanol (5mL) and the solution was treated with aqueous lithium hydroxide solution (2mL, 2M). After standing at room temperature for 2 hours the
15 mixture was acidified by addition of dilute acetic acid. The resulting white solid was collected by filtration, and sucked dry in the filter funnel to give the title compound (42mg) as a white amorphous solid. LC-MS: R_T = 2.29 minutes (100% by ELSD); MS (ES⁺), 443 (MH⁺).

EXAMPLE 3

20 (R) 3-{4-[2-(4-methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]}butanoic acid
A solution of ethyl (R) 3-{4-[2-(4-methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]}butanoate (0.17g, Reference Example 8) in methanol was treated with aqueous lithium hydroxide solution (5mL, 1M) and left to stand for five hours under argon. The mixture was acidified to pH 1 by addition of dilute hydrochloric acid, then partially evaporated, then diluted
25 with more water and then partially evaporated again. The residue was diluted with water to afford a tan solid which was filtered, then dissolved in saturated sodium bicarbonate solution. The solution was washed with ethyl acetate, then acidified to pH1 and then extracted with ethyl acetate several times. The combined ethyl acetate extracts were washed with brine and then evaporated to give the title compound (0.12g) as a white powder. LC-MS: R_T = 3.29 minutes
30 (100% by ELSD); MS (ES⁺), 474 (MH⁺).

EXAMPLE 4

(a) (R) 3-{4-[2-(4-Methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]-butanoic acid

A solution of ethyl (R) 3-{4-[2-(4-methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]-butanoate [0.14g, Reference Example 15(a)] in methanol (2mL) was treated with aqueous sodium hydroxide solution (1.2mL, 1M) and then stirred at 50°C for 2 hours. The mixture was diluted with water and partially evaporated. The residue was washed with diethyl ether and then acidified to pH 4. The precipitated solid was filtered and sucked dry to give the title compound (0.07g) as a tan solid. LC-MS: R_T = 3.38 minutes (100% by ELSD); MS (ES^+), 458 (MH^+).

(b) By proceeding in a manner similar to Example 4(a) but using ethyl (R) 3-{4-[2-(4-ethyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]butanoate [Reference Example 15(b)] there was prepared (R)3-{4-[2-(4-ethyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]butanoic acid.

LC-MS: R_T = 3.65 minutes (86% by ELSD); MS (ES^+), 472 (MH^+).

EXAMPLE 5

(R,S) 3-Phenyl-3-[4-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylaminophenyl]-propanoic acid

(R,S) Ethyl 3-(4-aminophenyl)-3-phenylpropanoate (620mg, Reference Example 19) and diisopropylethylamine (0.8mL) in dimethylformamide (10mL) were treated with a solution of (2-*o*-tolylamino-benzoxazol-6-yl)-acetic acid (650 mg, Reference Example 4) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (961mg) in dimethylformamide (10mL). The yellow solution was stirred at room temperature for 15hours then evaporated. The residue was partitioned between ethyl acetate (50mL) and 5% aqueous sodium carbonate (50mL). The organic layer was separated and the aqueous phase extracted with ethyl acetate (50mL). The combined organic phases were dried and then evaporated. The resulting yellow oil was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and pentane (1:1, v/v) to give a colourless gum. This material was dissolved in ethanol (20mL) and the solution was treated with 5% aqueous sodium hydroxide (20mL). The mixture was stirred at room temperature for 5hours then concentrated to remove the ethanol. The residue was partitioned between ethyl acetate (50mL) and hydrochloric acid (50mL, 1M). After separation of the layers the ethyl acetate phase was washed with water (50mL), then dried and then evaporated to give the title compound as an off white solid. LC-MS: R_T = 3.48 minutes (>93% by ELSD); MS (ES^+), 505 (MH^+).

EXAMPLE 6**(R)-3-{4-[3-(2-*o*-tolylamino-benzoxazol-6-yl)-propanoylamino]-phenyl}-butanoic acid**

A solution of ethyl 3(R)-{4-(N-tertiary-butyloxycarbonylamino)phenyl}butanoate (104mg, Reference Example 25) in a mixture of dichloromethane (5mL) and trifluoroacetic acid (3mL) was stirred at room temperature for 30 minutes then evaporated. The residue was dissolved in dimethylformamide (10mL) and the solution was treated successively with diisopropylethylamine (240mg), 3-(2-*o*-tolylamino-benzoxazol-6-yl)-propanoic acid (100mg, Reference Example 20) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (140mg). The resulting mixture was kept at room temperature overnight, then partitioned between ethyl acetate (50mL) and hydrochloric acid (50mL, 1M). The layers were separated and the organic phase was washed with 5% sodium bicarbonate solution, then dried and then evaporated. The residue was dissolved in methanol (50mL) and the solution was treated with sodium hydroxide solution (2mL, 1M). This mixture was stirred at 40°C for 2 hours then concentrated to low bulk, then diluted with water (30mL) and then acidified with hydrochloric acid (5mL, 1M). The resulting white precipitate was filtered, then washed with water and then dried to give the title compound (80mg) as a white solid. LC-MS: R_T = 3.28 minutes (100% by ELSD); MS (ES^+), 458 (MH^+).

EXAMPLE 7**6-Hydroxy-3-{4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-hexanoic acid**

A solution of ethyl 6-hydroxy-3-{4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-hexanoate [460mg, Reference Example 23 (a)] in a mixture of ethanol (30mL) and water (10mL) was treated with sodium hydroxide solution (5mL, 1M) and then heated at 40°C for 2 hours. The mixture was evaporated and the residue was dissolved in water (50mL). This solution was washed three times with ethyl acetate, then acidified with dilute hydrochloric acid (a white precipitate was formed) and then extracted three times with ethyl acetate. The combined extracts were washed with brine, then dried and then evaporated. The residual white foam was dissolved in sodium hydroxide solution (50mL, 0.5M) and the solution was washed twice with ether then acidified with dilute hydrochloric acid. The resulting white precipitate was filtered and then dried to give the title compound (250 mg) as a white solid. LC-MS: R_T = 2.88 minutes (100% by ELSD); MS (ES^+), 488 (MH^+).

EXAMPLE 8**Lithium 6-Hydroxy-3-(4-[2-(2-*o*-tolylamino-3*H*-benzimidazol-5-yl)-acetylamino]-phenyl)-hexanoate trifluoroacetate**

A solution of ethyl 6-hydroxy-3-(4-{2-[2-*o*-tolylamino-3-(2-trimethylsilanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetylamino}-phenyl)hexanoate (470mg, Reference Example 23 (b)) in a mixture of ethanol (20mL) and water (5mL) was treated with lithium hydroxide monohydrate (65 mg). This solution was heated at 40°C for 2 hours then evaporated. The residue was dissolved in water (20mL) and this solution was washed twice with ether then acidified with dilute hydrochloric acid to give a colourless gum (370mg). A portion of this material (50mg) was treated with trifluoroacetic acid (2mL) and the mixture was stirred at room temperature for 2 hours then evaporated. The residue was dissolved in a mixture of ethanol (4mL) and water (1mL) and the solution was treated with lithium hydroxide monohydrate (8mg). After stirring at room temperature for 90 minutes the mixture was filtered and the filtrate evaporated to dryness. The glassy residue was triturated with acetonitrile and the resultant solid was collected by filtration and dried to give the title compound (33 mg) as a white powder. LC-MS: $R_T = 2.11$ minutes (87% by ELSD); MS (ES^+), 487 (MH^+).

REFERENCE EXAMPLE 1**Ethyl 3(R)-(4-aminophenyl)butanoate**

A solution of ethyl 3(R)-(4-nitrophenyl)butanoate (4.0g, Reference Example 2) in ethanol (100mL) was treated with ammonium formate (about 15g). The reaction mixture was immersed in an oil-bath in a single neck flask, the solution was heated to 50°C, then treated with palladium on charcoal (about 1g, 5%) to give an immediate visible effervescence. The mixture was kept at 50°C with stirring for about an hour, then filtered through filter-aid. The filtrate was evaporated and the residue was partitioned between *tert*-butyl methyl ether and water. The organic phase was dried then evaporated to give the title compound (2.8g) as a light brown gum.

REFERENCE EXAMPLE 2**Ethyl 3(R)-(4-nitrophenyl)butanoate**

A solution of 3(R)-(4-nitrophenyl)butanoic acid (4.0g, Reference Example 3) in ethanol (60mL) was treated with concentrated hydrochloric acid (5 drops). The solution was refluxed for 2 hours and then evaporated. The residue was dissolved in *tert*-butyl methyl ether and the solution was washed with 5% aqueous sodium carbonate solution, then dried, and then evaporated to give the title compound (4.0g) as a white solid.

REFERENCE EXAMPLE 3**3(R)-(4-Nitrophenyl)butanoic acid**

(R)-3-phenylbutanoic acid (10.0g) was added to concentrated sulphuric acid (40mL) at -5°C under nitrogen. The resulting thick gel-like mixture was stirred vigorously and fuming nitric acid (2.8mL) was added slowly over 20 minutes. The reaction mixture was poured onto a mixture of ice and water (500mL) and the resulting white precipitate was collected by filtration, then washed thoroughly with water, and then dried to give the title compound (10.1g) as a white solid.

REFERENCE EXAMPLE 4**2-o-tolylaminobenzoxazole-6-acetic acid**

A mixture of ethyl 4-amino-3-hydroxy-phenylacetate (3.3g, Reference Example 5) and o-tolylisothiocyanate (2.5mL) in ethanol (150mL) was stirred at room temperature for about 2 hours. After standing at room temperature overnight the mixture was evaporated and the residue was subjected to flash chromatography (on silica eluting with a mixture of pentane and ethyl acetate, 7:3 v/v) to give a yellow foam. A solution of this material in ethanol (150mL) was treated with dicyclohexylcarbodiimide (3.0g) and the mixture was heated at reflux temperature for 2 hours. The mixture was evaporated and the residue subjected to short column chromatography (on silica eluting with a mixture of *tert*-butyl methyl ether and dichloromethane, 1:19 to 1:9 v/v). The resulting light yellow oil was dissolved in ethanol (100mL) and the solution was treated with sodium hydroxide solution (15mL, 1M) then heated at reflux temperature for 2 hours. The reaction mixture was evaporated and the residue was dissolved in water. The solution was washed with ethyl acetate and the aqueous layer was acidified to pH 1 by addition of concentrated hydrochloric acid. The resulting white precipitate was collected by filtration, then washed thoroughly with water, and then dried to give the title compound (1.8g) as a white solid.

REFERENCE EXAMPLE 5**Ethyl 4-amino-3-hydroxy-phenylacetate**

A solution of ethyl 3-hydroxy-4-nitrophenylacetate (5.0g, Reference Example 6) was dissolved in ethanol (approximately 200mL) was treated with ammonium formate (approximately 20g). The mixture was warmed to 50°C and then treated cautiously with palladium on charcoal (approximately 1g, 5%) - effervescence was observed. After 30 minutes the mixture was filtered hot through a pad of filter-aid and the filtrate was concentrated to give the title compound (3.3g) as a black solid.

REFERENCE EXAMPLE 6**Ethyl 3-hydroxy-4-nitrophenylacetate**

A solution of 3-hydroxy-4-nitrophenylacetic acid (4.0g, prepared according to the procedure described by Meyer et al, J. Med. Chem., 1997, 40, pages 1049-1062) in ethanol (approximately 100mL) was treated with concentrated hydrochloric acid (5-8 drops) was heated at reflux temperature for 3 hours then evaporated. The residue was dissolved in *tert*-butyl methyl ether and the solution was washed with saturated aqueous sodium bicarbonate solution, then with water, then dried, and then evaporated to give the title compound (5.0g) as a light yellow solid.

REFERENCE EXAMPLE 7**2-(2-*o*-tolylamino)benzimidazole-5-acetic acid hydrochloride**

A solution of ethyl 3,4-diaminophenylacetate (2.3 g, prepared according to the procedure described by Mederski et al, Biorg. Med. Chem. Lett, 1998, 8, pages 17-22) in ethanol (20mL) was treated with *o*-tolylisothiocyanate (3.0g). After stirring at room temperature for 4 hours the solution was evaporated. The residue was dissolved in ethanol (50mL) and the solution was treated with diisopropylcarbodiimide (3.0g). After stirring at 50°C for 4 hours the reaction mixture was evaporated. The residue was triturated with ether and filtered. The filtrate was evaporated and the residue was subjected to flash chromatography (on silica eluting with ether) to give a colourless gum (1.1g). This material was dissolved in ethanol (15mL) and the solution was treated with sodium hydroxide solution (5mL, 1M). After standing at room temperature for 3 hours the clear solution was evaporated to low bulk and the residue partitioned between ethyl acetate and hydrochloric acid (1M). The aqueous phase was evaporated and the residue was triturated with ethanol. The filtrate was evaporated to give the title compound (0.8g) as a beige foam.

REFERENCE EXAMPLE 8**Ethyl (R) 3-{4-[2-(4-methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetylamino]phenyl}butanoate**

A stirred solution of with ethyl (R) 3-(4-aminophenyl)butanoate (0.107g, Reference Example 1) in dimethylformamide (10mL) was treated with diisopropylethylamine (0.4g), 2-(4-methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid [0.105g, Reference Example 9(a)] and then with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.14g). The mixture was left to stand for 20 hours and then partitioned between ethyl acetate and hydrochloric acid (1M). The organic phase was washed with water, then with aqueous bicarbonate solution (5%), then with water, then with brine, then dried and then evaporated to give the title compound (0.17g) as a cream coloured solid.

REFERENCE EXAMPLE 9**(a) 2-(4-Methoxy-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid**

A mixture of methyl 4-amino-3-hydroxy-5-methoxy-phenylacetate [0.295g, Reference Example 10(a)] and *o*-tolylisothiocyanate (2.14g) in ethanol (25mL) was left at room temperature for 3 days. The mixture was evaporated and a solution of the residue in ethanol (20mL) was treated with dicyclohexylcarbodiimide (0.308g). The mixture was heated at reflux temperature for 2.5 hours and then evaporated. The resulting brown oil was dissolved in methanol (30mL) and the solution was treated with sodium hydroxide solution (10mL, 1M) and then heated at 45°C for one hour. The mixture was diluted with water and then partially evaporated. The residue was washed twice with diethyl ether and the pH of the aqueous phase was adjusted to 1-2 by addition of dilute hydrochloric acid. The mixture was then extracted with ethyl acetate and the organic phase was washed with water, then with brine, then dried and then evaporated to give the title compound (0.42g) as a golden solid.

(b) By proceeding in a similar manner to Reference Example 9(a) but using *t*-butyl 4-amino-3-hydroxy-5-methyl-phenylacetate [Reference Example 10(b)] there was prepared 2-(4-methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid as a pale yellow solid.

(c) By proceeding in a manner similar to Reference Example 9(a) but using *t*-butyl 4-amino-3-hydroxy-5-ethyl-phenylacetate [Reference Example 10(c)] there was prepared 2-(4-ethyl-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid.

REFERENCE EXAMPLE 10**(a) Methyl 4-amino-3-hydroxy-5-methoxy-phenylacetate**

A solution of methyl 3-hydroxy-5-methoxy-4-nitrophenylacetate (0.34g, Reference Example 11) in ethanol (25mL) was treated with palladium on charcoal (approximately 0.035g, 10%) and stirred under a hydrogen atmosphere. After 2 hours the mixture was filtered through a pad of celite and the filtrate was evaporated to give the title compound (0.3 g) as a brown oil.

(b) By proceeding in a manner similar to Reference Example 10(a) but using *t*-butyl 3-hydroxy-5-methyl-4-nitrophenylacetate [Reference Example 16(a)] there was prepared *t*-Butyl 4-amino-3-hydroxy-5-methyl-phenylacetate as a green oil.

(c) By proceeding in a manner similar to Reference Example 10(a) but using *t*-butyl 3-hydroxy-5-ethyl-4-nitrophenylacetate [Reference Example 16(a)] there was prepared *t*-butyl 4-amino-3-hydroxy-5-methyl-phenylacetate.

REFERENCE EXAMPLE 11

Methyl 3-hydroxy-5-methoxy-4-nitrophenylacetate

A solution of 3-hydroxy-5-methoxy-4-nitrophenylacetic acid (0.76g, Reference Example 12) in methanol (100mL) and concentrated hydrochloric acid (5 drops) was heated at reflux through 3A molecular sieve for 4 hours, then evaporated. The residue was partitioned between ethyl acetate and water. The organic phase was washed with water, then with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with dichloromethane, then with a mixture of methanol and dichloromethane (1:49, v/v) to give the title compound (0.34g).

REFERENCE EXAMPLE 12

3-Hydroxy-5-methoxy-4-nitrophenylacetic acid

A stirred mixture of 3,5-dimethoxy-4-nitrophenylacetic acid (0.4g, Reference Example 13) and pyridine hydrochloride (6g) was heated at 145°C, under argon, for 4 hours. The cooled reaction mixture was partitioned between ethyl acetate and water. The organic phase was washed with water, then with brine, then dried and then evaporated to give a 1:1 mixture of the title compound and starting material (0.37g) which was used without further purification.

REFERENCE EXAMPLE 13

3,5-Dimethoxy-4-nitrophenylacetic acid

A stirred solution of *t*-butyl 3,5-difluoro-4-nitrophenylacetate (4.5g, Reference Example 14) in methanol (350mL) was treated with sodium methoxide in methanol (36g, 25 wt %) and then heated at reflux for 18 hours. The cooled reaction mixture was carefully acidified to pH 2 by addition of dilute hydrochloric acid and then partially evaporated to remove the methanol. The aqueous residue was extracted twice with ethyl acetate. The combined extracts were extracted into saturated sodium bicarbonate solution. The aqueous extract was acidified to pH 2 and extracted with twice with ethyl acetate, then dried and then evaporated to give the title compound (1.4g) as a brown solid.

REFERENCE EXAMPLE 14***t*-Butyl 3,5-difluoro-4-nitrophenylacetate**

A stirred solution of potassium *t*-butoxide (8.4g) in dimethylformamide (150mL), under nitrogen and at -10° to -12°C, was treated dropwise with a mixture of 2,6-difluoronitrobenzene (5.0g) and *t*-butyl chloroacetate (7.5mL) in dimethylformamide (150mL) over 30 minutes. After stirring for a further 1 hour the mixture was added to ice chilled hydrochloric acid (300mL, 1M) and the mixture was extracted three times with pentane. The combined extracts were dried and then evaporated to give a brown oil which was subjected to flash chromatography on silica eluting with a mixture of dichloromethane and pentane mixture (1:1, v/v) to give the title compound (3.5g) as a golden oil.

REFERENCE EXAMPLE 15**(a) Ethyl (R) 3-{4-[2-(4-methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]butanoate**

A stirred solution of 2-(4-methyl-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid [0.1g, Reference Example 9(b)] in dimethylformamide (3mL) was treated with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (0.128g), diisopropylethylamine (0.22g) and after 5 minutes with ethyl (R) 3-(4-aminophenyl)butanoate (0.107g, Reference Example 1). After 4 hours the reaction mixture was diluted with ethyl acetate and then washed with water, then with hydrochloric acid (1M), then twice with water, then with brine, then dried and then evaporated to give the title compound (0.15g) as a brown oil.

(b) By proceeding in a manner similar to Reference Example 15(a) but using 2-(4-ethyl-2-*o*-tolylaminobenzoxazol-6-yl)acetic acid [Reference Example 9(c)] there was prepared ethyl (R) 3-{4-[2-(4-ethyl-2-*o*-tolylaminobenzoxazol-6-yl)acetylaminophenyl]butanoate.

REFERENCE EXAMPLE 16**(a) *t*-Butyl 3-hydroxy-5-methyl-4-nitrophenylacetate**

A solution of *t*-butyl 3-acetoxy-5-methyl-4-nitrophenylacetate [0.5g, Reference Example 17(a)] in methanol (6mL) was treated with lithium hydroxide (0.2g) in water (1.5mL). After stirring for 2 hours the mixture was carefully acidified to pH 5 and then treated with ethyl acetate and sodium chloride. The organic layer was evaporated and the residue was dissolved in dichloromethane. This solution was dried and then evaporated to give the title compound (0.45g) as a yellow green oil.

(b) By proceeding in a manner similar to Reference Example 16(a) but using *t*-butyl 3-acetoxy-5-ethyl-4-nitrophenylacetate [Reference Example 17(b)] there was prepared *t*-butyl 3-hydroxy-5-ethyl-4-nitrophenylacetate.

5

REFERENCE EXAMPLE 17

(a) *t*-Butyl 3-acetoxy-5-methyl-4-nitrophenylacetate

A stirred solution of *t*-butyl 3-acetoxy-4-nitrophenylacetate (8.0g, Reference Example 18) in tetrahydrofuran (350mL) at -15°C under argon was treated dropwise with methyl magnesium chloride solution in diethyl ether (7mL, 3M) and after 2 hours a further aliquot of methyl
10 magnesium chloride solution in diethyl ether (7mL, 3M). After stirring for a further 1 hour the reaction mixture was treated with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (10.4g), then stirred at room temperature overnight, then partially evaporated and then treated with dichloromethane. The mixture was washed with water, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with dichloromethane to give the
15 title compound (1.66g) as a yellow oil.

(b) By proceeding in a manner similar to Reference Example 17(a) but using ethyl magnesium chloride there was prepared *t*-butyl 3-acetoxy-5-ethyl-4-nitrophenylacetate.

20

REFERENCE EXAMPLE 18

t-Butyl 3-acetoxy-4-nitrophenylacetate

A stirred suspension of 3-acetoxy-4-nitrobenzoic acid (10.5g) in dichloromethane (100mL) was treated with oxalyl chloride (33mL) and then dimethylformamide (2 drops). After stirring at room temperature over night the mixture was evaporated. The residue was dissolved in
25 acetonitrile (100mL) and this solution was added dropwise to a stirred mixture of trimethylsilyldiazomethane (25mL, 2M in hexanes) and triethylamine (5.05g) in acetonitrile (50mL) at 0°C under nitrogen and stirring at 0°C was continued overnight. The mixture was evaporated and then partitioned between ethyl acetate and saturated sodium bicarbonate solution. The organic phase was dried and then evaporated. The residue was dissolved in
30 refluxing *t*-butanol and then treated dropwise with a solution of silver benzoate (2.8g) in triethylamine (15mL) over 30 minutes. After standing for 30 minutes the cooled reaction mixture was evaporated and then partitioned between ethyl acetate and hydrochloric acid (1M). The organic phase was washed with saturated sodium bicarbonate solution, then dried and then evaporated to give the title compound (10.6g) as a viscous brown oil.

35

REFERENCE EXAMPLE 19**(R,S) Ethyl 3-(4-aminophenyl)-3-phenylpropanoate**

A solution of (E/Z) ethyl 3-(4-nitrophenyl)-cinnamate (1.82g, prepared according to the procedure described by F. Himmelsbach et al in European Patent Application Number EP 612741 A1) in ethyl acetate (20mL) was hydrogenated at 35°C using 10% palladium on charcoal (200mg) as catalyst. After 24 hours, the degassed mixture was filtered through a pad of diatomaceous earth and the filtrate was evaporated to dryness to give the title compound as an oil.

REFERENCE EXAMPLE 20**3-(2-*o*-tolylamino-benzoxazol-6-yl)-propanoic acid**

A solution of ethyl 3-(4-amino-3-hydroxyphenyl)propanoate (1.9g, prepared according to the procedure described by T. Mase et al in World Patent Application Number 8605779 A1) in ethanol (50mL) was treated with *o*-tolyl isothiocyanate (1.7g). The mixture was warmed at about 40°C for 2 hours and then evaporated. A solution of the residue in ethanol (50mL) was treated with diisopropylcarbodiimide (3mL) and the mixture was heated at about 40°C for 1 hour and then evaporated. The residue was triturated with ether (50mL) and the insoluble materials filtered. The filtrate was evaporated and the residue subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (2:3, v/v) to give a colourless oil (1.6g) which was dissolved in methanol (50mL). The methanol solution was treated with sodium hydroxide solution (5mL, 1M). After stirring at 40°C for 2 hours the mixture was evaporated to low bulk and the residue was partitioned between ethyl acetate (50mL) and water (50mL). The aqueous phase was treated with hydrochloric acid (10mL, 1M) and the resulting white precipitate was filtered, then washed with water and then dried to give the title compound (1.1g) as a white powder.

REFERENCE EXAMPLE 21**Ethyl 6-benzyloxy-3-{4-(N-tertiary-butyloxycarbonylamino)phenyl}-2-hexenoate and ethyl 6-benzyloxy-3-{4-(N-tertiary-butyloxycarbonylamino)phenyl}-3-hexenoate**

A mixture of N-tertiary-butyloxycarbonyl-4-iodoaniline (2.0g), ethyl 6-benzyloxy-2-hexenoate (3.2g, prepared according to the procedure described by D. Ma & J. Zhang, J. Chem. Soc., Perkin Trans. 1, 1999, pp1703 to 1708), palladium acetate (145mg), tris (*o*-tolyl)phosphine (390mg), and triethylamine (2.2mL) in dimethylformamide (10mL) was stirred in a sealed tube under a nitrogen atmosphere for 2 days. Further palladium acetate (50mg), tris (*o*-tolyl)phosphine (100mg), and N-tertiary-butyloxycarbonyl-4-iodoaniline (520mg) were added

and heating was continued for a further 18 hours. After cooling to room temperature the reaction mixture was poured into water and extracted three times with ether. The combined extracts were washed with dilute hydrochloric acid, then with brine, then dried over magnesium sulphate and then evaporated. The residual brown solid (6g) was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether (1:9, v/v) to give in order of elution: ethyl 6-benzyloxy-2-hexenoate as a colourless oil; ethyl 6-benzyloxy-3-{4-(N-tertiary-butyloxycarbonylamino)phenyl}-2-hexenoate (730mg) as a yellow oil; and ethyl 6-benzyloxy-3-{4-(N-tertiary-butyloxycarbonylamino)phenyl}-3-hexenoate (2.1g) as an oily solid. The latter oily solid was triturated with ether and the mixture was filtered. The filtrate was evaporated to give the title compound (1.6g) as a yellow oil.

REFERENCE EXAMPLE 22

(a) Ethyl 6-benzyloxy-3-{4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-3-hexenoate

A solution of ethyl 6-benzyloxy-3-{4-(N-tertiary-butyloxycarbonylamino)phenyl}-3-hexenoate (580mg, Reference Example 21) in a mixture of trifluoroacetic acid (10mL) and dichloromethane (15mL) was kept at room temperature for 90 minutes and then evaporated. The residue was dissolved in dimethylformamide and the solution was treated successively with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (500mg), 2-(*o*-tolylaminobenzoxazol-6-yl)acetic acid (380mg, Reference Example 4) and diisopropylethylamine (1.2mL). This mixture was kept at room temperature for 2 hours then poured onto dilute hydrochloric acid and then extracted three times with ethyl acetate. The combined organic extracts were washed with brine, then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and petroleum ether mixture (2:3, v/v) to give the title compound (680 mg) as a light yellow oil.

(b) By proceeding in a manner similar to Reference Example 22(a) but using [2-*o*-tolylamino-3-(2-trimethylsilylanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetic acid (Reference Example 24) there was prepared ethyl 6-benzyloxy-3-{4-[2-[2-*o*-tolylamino-3-(2-trimethylsilylanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetylamino]-phenyl}-3-hexenoate.

REFERENCE EXAMPLE 23

(a) Ethyl 6-hydroxy-3-{4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-hexanoate

A mixture of ethyl 6-benzyloxy-3-{4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-3-hexenoate (640mg, Reference Example 22(a)) and 10% palladium on charcoal (250mg) in ethanol (50mL) was hydrogenated at room temperature and pressure. After 24 hours further catalyst

(200mg) was added and the mixture again subjected to a hydrogen atmosphere for a further 24 hours. The mixture was filtered through filter-aid and the filtrate evaporated to dryness to give the title compound (460 mg) as a colourless oil.

5 (b) By proceeding in a manner similar to Reference Example 23(a) but using ethyl 6-benzyloxy-3-(4-{2-[2-*o*-tolylamino-3-(2-trimethylsilylanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetylamino}-phenyl)-3-hexenoate (Reference Example 22(b)) there was prepared ethyl 6-hydroxy-3-(4-{2-[2-*o*-tolylamino-3-(2-trimethylsilylanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetylamino}-phenyl)hexanoate

REFERENCE EXAMPLE 24

[2-*o*-tolylamino-3-(2-trimethylsilylanyl-ethoxymethyl)-3*H*-benzimidazol-5-yl]-acetic acid

A solution of ethyl 3,4-diaminophenylacetate (5.8g, prepared according to the procedure described by Mederski et al, Biorg. Med. Chem. Lett, 1998, 8, pages17-22) in ethanol (40mL) was
15 treated with *o*-tolylisothiocyanate (4.9g). After stirring at room temperature for 4 hours the solution was evaporated. A stirred solution of the residue in ethanol (100mL) was treated with diisopropylcarbodiimide (7.6g), then heated at reflux temperature for 6 hours and then evaporated. The residue was subjected to flash chromatography on silica eluting with ether to give a yellow gum (5.2g). A solution of this product (5.0g) in tetrahydrofuran (200mL) was
20 treated with sodium hydride (710mg of a 60 % suspension in oil) under a nitrogen atmosphere and after stirring at room temperature for 30 minutes this mixture was treated with 2-trimethylsilylanyl-ethoxymethyl chloride (2.95g). After stirring at room temperature for a further 1 hour the mixture was evaporated to low bulk and the residue was partitioned between ethyl acetate (500mL) and water (500mL). The organic phase was dried and then evaporated.
25 The residue was subjected to flash chromatography on silica eluting with a mixture of pentane and ether (3:2, v/v) then with ether to give a white foam (5.2g). This material was dissolved in methanol (100mL) and the solution was treated with sodium hydroxide solution (30mL, 1M). After standing at room temperature for 4 hours the clear solution was evaporated to low bulk and then treated with water (50mL). The mixture was acidified with acetic acid to give a white
30 gummy precipitate. After careful decantation of the supernatant liquors the gum was dissolved in the minimum of ethanol. After standing for some time a white precipitate formed. The precipitate was collected by filtration and then dried to give the title compound (0.9g) as a white powder.

REFERENCE EXAMPLE 25

Ethyl 3(R)-(4-(N-tertiary-butyloxycarbonylamino)phenyl)butanoate

A stirred solution of ethyl 3(R)-(4-aminophenyl)butanoate (10g, Reference Example 1) in tetrahydrofuran (100mL) was treated with tertiary-butyloxycarbonyl anhydride (12.6g) and then heated at reflux temperature for 5 hours. The reaction mixture was evaporated and the residue was subjected to flash chromatography on silica eluting with a mixture of ether and pentane mixture (1:4, v/v) to give the title compound (10g) as a colourless oil which slowly crystallised on standing.

IN VITRO AND IN VIVO TEST PROCEDURES

1. Inhibitory effects of compounds on VLA4 dependent cell adhesion to Fibronectin and VCAM.

1.1 Metabolic labelling of RAMOS cells.

RAMOS cells (a pre-B cell line from ECACC, Porton Down, UK) are cultured in RPMI culture medium (Gibco, UK) supplemented with 5% foetal calf serum (FCS, Gibco, UK). Prior to assay the cells are suspended at a concentration of 0.5×10^6 cells/ml RPMI and labelled with $400\mu\text{Ci}/100\text{mls}$ of $[^3\text{H}]$ -methionine (Amersham, UK) for 18 hours at 37°C .

1.2 96 well plate preparation for adhesion assay.

Cytostar plates (Amersham, UK) were coated with $50\mu\text{l}/\text{well}$ of either $3\mu\text{g}/\text{ml}$ human soluble VCAM-1 (R&D Systems Ltd, UK) or $28.8\mu\text{g}/\text{ml}$ human tissue Fibronectin (Sigma, UK). In control non-specific binding wells $50\mu\text{l}$ phosphate buffered saline was added. The plates were then left to dry in an incubator at 25°C , overnight. The next day the plates were blocked with $200\mu\text{l}/\text{well}$ of Pucks buffer (Gibco, UK) supplemented with 1% BSA (Sigma, UK). The plates were left at room temperature in the dark for 2 hours. The blocking buffer was then disposed of and the plates dried by inverting the plate and gently tapping it on a paper tissue. $50\mu\text{l}/\text{well}$ of 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride (to activate the integrin receptor Sigma, UK) and 0.2% BSA (Sigma, UK), was added to the appropriate control test binding and non-specific binding assay wells in the plate. $50\mu\text{l}/\text{well}$ of the test compounds at the appropriate concentrations diluted in 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride and 0.2% BSA, was added to the test wells.

Metabolically labelled cells were suspended at 4×10^6 cells/ml in Pucks buffer that was supplemented with manganese chloride and BSA as above. 50µl/well of cells in 3.6% dimethyl sulphoxide in Pucks buffer and supplements was added to all plate wells.

The same procedure exists for plates coated with either VCAM-1 or fibronectin and data is
5 determined for compound inhibition of cell binding to both substrates.

1.3 Performance of assay and data analysis.

The plates containing cells in control or compound test wells are incubated in the dark at room temperature for 1 hour.

10 The plates are then counted on a Wallac Microbeta scintillation counter (Wallac, UK) and the captured data processed in Microsoft Excel (Microsoft, US). The data was expressed as an IC₅₀, namely the concentration of inhibitor at which 50% of control binding occurs. The percentage binding is determined from the equation:

15
$$\{[(C_{TB} - C_{NS}) - (C_I - C_{NS})] / (C_{TB} - C_{NS})\} \times 100 = \% \text{ binding}$$

where C_{TB} are the counts bound to fibronectin (or VCAM-1) coated wells without inhibitor present, C_{NS} are the counts present in wells without substrate, and C_I are the counts present in wells containing a cell adhesion inhibitor.

20

Compound data of this invention is expressed for IC₅₀s for inhibition of cell adhesion to both fibronectin and VCAM-1. Particular compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC₅₀'s in the range 100 micromolar to 1 nanomolar. Preferred compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC₅₀'s in the
25 range 10 nanomolar to 1 nanomolar.

2. Inhibition of antigen-induced airway inflammation in the mouse and rat.

2.1 Sensitization of the animals.

30 Rats (Brown Norway, Harland Olac, UK) are sensitized on days 0, 12 and 21 with ovalbumin (100 µg, intraperitoneally [i.p], Sigma, UK) administered with aluminium hydroxide adjuvant (100mg, i.p., Sigma, UK) in saline (1ml, i.p.).

In addition mice (C57) are sensitized on days 0 and 12 with ovalbumin (10µg, i.p.) administered with aluminium hydroxide adjuvant (20mg, i.p.) in saline (0.2ml, i.p.).

2.2 Antigen challenge.

Rats are challenged on any one day between days 28-38, while mice are challenged on any one day between days 20-30.

- 5 The animals are challenged by exposure for 30 minutes (rats) or 1 hour (mice) to an aerosol of ovalbumin (10g / l) generated by an ultrasonic nebulizer (deVilbiss Ultraneb, US) and passed into an exposure chamber.

2.3 Treatment protocols.

- 10 Animals are treated as required before or after antigen challenge. The aqueous-soluble compounds of this invention can be prepared in water (for oral, p.o. dosing) or saline (for intratracheal, i.t. dosing). Non-soluble compounds are prepared as suspensions by grinding and sonicating the solid in 0.5 % methyl cellulose / 0.2 % polysorbate 80 in water (for p.o. dosing, both Merck UK Ltd., UK) or saline (for i.t. dosing). Dose volumes are: for rats 1ml / kg, p.o. or
15 0.5mg / kg, i.t.; for mice 10ml / kg, p.o. or 1ml / kg, i.t.

2.4 Assessment of airway inflammation.

The cell accumulation in the lung is assessed 24 hours after challenge (rats) or 48-72 hours after challenge (mice). The animals are euthanized with sodium pentobarbitone (200mg/kg, i.p.,
20 Pasteur Merieux, France) and the trachea is immediately cannulated. Cells are recovered from the airway lumen by bronchoalveolar lavage (BAL) and from the lung tissue by enzymatic (collagenase, Sigma, UK) disaggregation as follows.

- BAL is performed by flushing the airways with 2 aliquots (each 10 ml/kg) RPMI 1640 medium (Gibco, UK) containing 10 % fetal calf serum (FCS, Serotec Ltd., UK). The recovered BAL
25 aliquots are pooled and cell counts made as described below.

- Immediately after BAL, the lung vasculature is flushed with RPMI 1640 / FCS to remove the blood pool of cells. The lung lobes are removed and cut into 0.5 mm pieces. Samples (rats: 400mg; mice: 150mg) of homogenous lung tissue are incubated in RPMI 1640 / FCS with collagenase (20 U/ml for 2 hours, then 60 U/ml for 1 hour, 37°C) to disaggregate cells from the
30 tissue. Recovered cells are washed in RPMI 1640 / FCS.

- Counts of total leukocytes recovered from the airway lumen and the lung tissue are made with an automated cell counter (Cobas Argos, US). Differential counts of eosinophils, neutrophils and mononuclear cells are made by light microscopy of cytocentrifuge preparations stained with Wright-Giemsa stain (Sigma, UK). T cells are counted by flow cytometry (EPICS XL, Coulter
35 Electronics, US) using fluophore-labelled antibodies against CD2 (a pan-T cell marker used to


quantify total T cells), CD4, CD8 and CD25 (a marker of activated T cells). All antibodies were supplied by Serotec Ltd., UK)

2.5 Data analysis.

- 5 The cell data was expressed as mean cell numbers in unchallenged, challenged and vehicle treated, and challenged and compound treated groups, including the standard error of the means. Statistical analysis of the difference among treatment groups was evaluated using one-way analysis of variance via the Mann-Whitney test. Where $p < 0.05$ no statistical significance existed.**

CLAIMS

1. A compound of general formula (I):-



wherein:-

Het represents an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N;

10 R^1 represents optionally substituted aryl or optionally substituted heteroaryl;

R^2 represents hydrogen, halogen, lower alkyl or lower alkoxy;

R^3 is an alkylene chain, an alkenylene chain or an alkynylene chain;

R^4 is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroaryldiyl, $-C(=Z^2)-NR^5-$, $-NR^5-C(=Z^2)-$, $-Z^2-$, $-C(=O)-$, $-C(=NOR^5)-$, $-NR^5-$, $-NR^5-C(=Z^2)-NR^5-$, $-SO_2-NR^5-$, $-NR^5-SO_2-$,

15 $-O-C(=O)-$, $-C(=O)-O-$, $-NR^5-C(=O)-O-$ or $-O-C(=O)-NR^5-$;

R^5 represents hydrogen or lower alkyl;

R^6 represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkylalkenyl, cycloalkylalkynyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

20 L^1 represents a $-R^3-R^4-$ linkage;

L^2 represents an alkylene or alkenylene linkage each optionally substituted by R^6 or by alkyl substituted by hydroxy, $-OR^6$, $-O-C(=O)-R^6$ or $-NY^1Y^2$;

Y is carboxy or an acid bioisostere;


Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or 25 heteroarylalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;



Z^1 represents NR^5 ; and




Z^2 is O or S;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs, but excluding compounds where


an oxygen, nitrogen or sulphur atom is attached directly to a carbon-carbon multiple bond of an alkenyl, alkenylene, alkynyl, alkynylene or cycloalkenyl residue.

2. A compound according to claim 1 in which Het represents , wherein ring

5  is a 5 or 6 membered heterocycle and ring  is a 5 or 6 membered fully unsaturated heterocycle or a benzene ring, each ring optionally substituted, and the two rings are joined together by a carbon-carbon linkage or a carbon-nitrogen linkage.

3. A compound according to claim 1 in which Het represents an optionally substituted 9
10 membered bicyclic system  in which ring  is a 5 membered fully unsaturated heterocycle,  is an optionally substituted benzene and the two rings are joined together by carbon atom linkages.

4. A compound according to claim 1 in which Het represents optionally substituted
15 benzoxazolyl or optionally substituted benzimidazolyl in which the benzene ring contains the optional substituent.

5. A compound according to any preceding claim in which ring  is a benzene ring optionally substituted by one of C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, halogen, hydroxy, C₁₋₄ alkylthio,
20 C₁₋₄ alkylsulphinyl, C₁₋₄ alkylsulphonyl, nitro or trifluoromethyl.

6. A compound according to any preceding claim in which R¹ represents optionally substituted phenyl.

25 7. A compound according to any preceding claim in which Z¹ represents NH.

8. A compound according to any preceding claim in which L^1 represents a $-R^3-R^4-$ linkage where R^3 is a straight or branched C_{1-4} alkylene chain, and R^4 represents $-C(=O)-NR^5-$ where R^5 is hydrogen or C_{1-4} alkyl.

5

9. A compound according to any preceding claim in which R^2 represents hydrogen.

10. A compound according to any preceding claim in which L^2 represents a C_{1-4} alkylene linkage optionally substituted by C_{1-4} alkyl, optionally substituted phenyl, or by alkyl

10 substituted by hydroxy, $-OR^6$, $-O-C(=O)-R^6$ or $-NY^1Y^2$.

11. A compound according to any preceding claim in which L^2 represents ethylene optionally substituted by C_{1-4} alkyl, optionally substituted phenyl, or by alkyl substituted by hydroxy, $-OR^6$, $-O-C(=O)-R^6$ or $-NY^1Y^2$.

15

12. A compound according to any preceding claim in which L^2 represents $\begin{array}{c} R^7 \\ | \\ -C-CH_2- \\ | \\ R^8 \end{array}$,

where R^7 and R^8 are both independently hydrogen or C_{1-4} alkyl, or where R^7 is hydrogen and R^8 represents optionally substituted phenyl or alkyl substituted by hydroxy, $-OR^4$, $-O-C(=O)-R^6$ or $-NY^1Y^2$.

20


13. A compound according to any preceding claim in which L^2 represents $\begin{array}{c} -CH-CH_2- \\ | \\ R^8 \end{array}$

where R^8 is C_{1-4} alkyl, optionally substituted phenyl, or C_{1-4} alkyl substituted by hydroxy, $-OR^6$, $-O-C(=O)-R^6$ or $-NY^1Y^2$.

25

14. A compound according to any preceding claim in which Y is carboxy.

15. A compound of formula (Ia):-



(Ia)


in which R^1 , R^2 , R^3 , R^5 , L^2 , Y and Z^1 are as defined in any relevant preceding claim, R^{13} is selected from acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydrogen, hydroxy, nitro, trifluoromethyl, Y^1Y^2N- , Y^1Y^2NCO- , $Y^1Y^2NSO_2-$, $Y^1Y^2N-C_{2-6}alkylene-Z^1-$, alkylC(=O)- Y^1N- , alkylSO₂- Y^1N- or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y^1Y^2N- , and X is O or NR^9 (in which R^9 is hydrogen or C_{1-4} alkyl), and their prodrugs and pharmaceutically acceptable salts, and solvates of compounds of formula (Ia) and their prodrugs.

16. A compound according to claim 15 in which R^{13} represents hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy.

17. A compound according to claim 15 or claim 16 in which R^3 represents methylene.

18. A compound according to any one of claims 15 to 17 in which R^5 represents hydrogen.

19. A compound according to any one of claims 15 to 18 in which the group



is attached at the ring 6 position when X is O or NH, or at the

ring 5 or 6 position when X is NR^9 and R^9 is C_{1-4} alkyl.

20. A compound according to any one of claims 15 to 19 in which the group $\text{---L}^2\text{---Y}$ is attached at the 4' position of the phenyl ring.

5 21. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide prodrug thereof, in association with a pharmaceutically acceptable carrier or excipient.

10 22. A compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, for use in therapy.

15 23. A compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

20 24. A composition according to claim 21 for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

25 25. A compound or composition according to claim 1 or 21 respectively for use in the treatment of inflammatory diseases.

26. A compound or composition according to claim 1 or 21 respectively for use in the treatment of asthma.

30 27. Use of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, in the manufacture of a medicament for the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

28. Use of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, in the manufacture of a medicament for the treatment of asthma.

5 29. A method for the treatment of a human or non-human animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.

10

30. A compound as substantially hereinbefore described with references to the Examples.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 00/00553

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/58 C07D235/30 C07D413/12 C07D401/12 C07D405/12
C07D409/12 A61K31/423 A61K31/4184 A61P29/00 A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 36862 A (G.D. SEARLE & CO.) 9 October 1997 (1997-10-09) the whole document, particularly example 69	1,21-29
P,X	WO 00 05223 A (ZENECA LIMITED) 3 February 2000 (2000-02-03) the whole document	1-30
P,X	WO 00 05224 A (ZENECAL LIMITED) 3 February 2000 (2000-02-03) the whole document	1-30

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

23 May 2000

Date of mailing of the international search report

06/06/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3018

Authorized officer

Allard, M

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB 00/00553

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-14 and 21-29 relate to an extremely large number of possible compounds and their use. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, said claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the scope of said claims is impossible. Consequently, the search has been carried out for those parts of said claims which appear to be supported and disclosed, namely those parts relating to the compounds resulting from all possible combinations of the fragments mentioned in tables 1-3 of the description.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/GB 00/00553

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9736862	A	09-10-1997	AU 2337097 A	22-10-1997
			CA 2250464 A	09-10-1997
			EP 0889877 A	13-01-1999
			US 5773646 A	30-06-1998
WO 0005223	A	03-02-2000	NONE	
WO 0005224	A	03-02-2000	NONE	